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Abstract
Parkinson’s disease (PD) is a chronic and progressive neurological disorder that
causes both motor symptoms and non-motor symptoms in individuals. Overall, PD
impacts the physical, emotional and social functioning in the lives of those impacted by
the disorder. In 2001, Freed et al. investigated the effects of fetal tissue transplantation in
participants with PD by conducting a double-blind sham-controlled surgery trial. The
quality of life (QoL) study was conducted concurrently by McRae et al. (2004) in order to
determine whether QoL improved in participants in the transplant group compared to the
sham group after the one-year period of the double-blind.
Research regarding the long-term impact of the fetal tissue transplantation on
individuals with PD is extremely limited and there is little known regarding the long-term
impact of participating in a double-blind sham-controlled surgery trial. This study
examined the longitudinal changes, from both a quantitative and qualitative perspective,
in QoL after undergoing the fetal tissue transplantation surgery approximately 13-15
years ago. There were a total of five participants who participated in the parent study
(Freed et al., 2001) and original QoL study (McRae, 2004). All five participants
completed an interview to gather qualitative information regarding their personal
experiences over the last 13-15 years and four participants completed a questionnaire that
measured several dimensions of QoL as well as optimism. The information gathered in
the current study was plotted along with the data collected at baseline, 12, and 24 months
after transplantation as well as a previous follow-up in 2008. The change over time in
ii

QoL was thus charted for each of the four individuals as well as average scores at each
time point on each measure. Interviews were transcribed and coded for themes in order to
describe the experiences of the participants in the unique study.
In the current study, the changes on several aspects of QoL were examined over
the last 13-15 years. The majority of the participants showed decline on all the measures
assessing Physical functioning, Emotional functioning, and Social functioning as well as
Optimism between the 10-12-year follow-up in 2008 and the current assessment.
However, the decline in functioning on several measures was less than expected given the
progression of their illness. The qualitative data (e.g., narratives) provided insight into
possible explanations for the resiliency amongst the participants who participated in the
transplant surgery trial including the participants’ dedication to contributing to our
knowledge of PD and treatments of PD, strong social support, and internal drive to
continue to live active and meaningful lives.
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Chapter One
Introduction
Description of Parkinson’s Disease
Parkinson’s disease (PD) is a chronic neurologic disease that impacts the central
nervous system. James Parkinson, a British physician, described a complex set of
symptoms in 1817 that later became known as Parkinson’s disease. PD is characterized
by motor symptoms including bradykinesia, resting tremor, stiffness, postural instability,
and a broad spectrum of non-motor features including sleep problems, autonomous
nervous system dysfunction, depression and dementia (Burch & Sheerin, 2005; Pfeiffer,
2007; Rod, Hansen, Schernhammer & Ritz, 2010).
PD is the result of a loss of dopaminergic neurons in the substantia nigra pars
compacta, which causes reduced dopamine release in the striatum (Clark, Reddy, Zheng,
Betensky & Simon, 2011). There are multiple genetic and environmental factors
involved in PD (Simunovic et al., 2009). Currently, there are two forms of PD
recognized: a ‘familial’ or early-onset PD and an ‘idiopathic’ or late-onset PD that does
not appear to exhibit heritability (Simunovic et al., 2009). The ‘familial’ or early-onset
PD is found in approximately less than10% of all PD patients and ‘idiopathic’ or lateonset PD is found in approximately more than 85% of all PD patients. Overall, the
pathology of Parkinson's disease is a consequence of a combination of unknown genetic
and environmental factors, which leads to a common pathogenic cascade of molecular
1

events (Maguire-Zeiss & Federoff, 2003; Miller & Federoff, 2005; Simunovic et al.,
2009).
PD is currently diagnosed based on clinical criteria, and at this time, there is no
definitive test for PD. Diagnosis is generally based on the presence or absence of
cardinal motor features associated with PD (e.g., tremors, rigidity, bradykinesia) and
response to Levodopa (Rao et al., 2003). The diagnosis of PD can often be challenging,
particularly in the early stages of the disease when there is overlap between the
symptoms in different syndromes (Jankovic, 2008; Tolosa, Wenning & Poewe, 2006).
Persons with PD can sometimes be misdiagnosed for several years before the symptoms
become obvious enough for a clear diagnosis.
The treatments for PD include drug therapies and surgical interventions targeted
at reducing the symptoms associated with PD. The surgical procedures are implemented
when drug treatments are no longer effective in the later stages of the disease. Current
surgical treatments for patients with PD include thalamotomy, pallidotomy, and deep
brain stimulation. Gene therapy, stem cell transplantation, and fetal tissue transplantation
are additional surgical interventions for patients with PD that are in various stages of
development and refinement.
Onset and Prevalence
Today, PD is the most prevalent neurodegenerative movement disorder in adults
(Borland et al., 2008). PD affects up to one million people in the United States (National
Parkinson Foundation, 2010). More specifically, the disease affects approximately 2-3%
of individuals over the age of 65 years (Cantuti-Castelvetri et al., 2007). However, in 510% of people who develop Parkinson's disease, the condition appears before the age of
2

40. Overall, age-adjusted prevalence is 1% worldwide, and 1.6% in Europe, rising from
0.6% at age 60-64 to 3.5% at age 85-89 (Clark & Moore, 2007; De Rijk et al., 1997;
Zhang & Roman, 1993).
While the progression and symptoms of PD vary significantly among patients,
research has found that bradykinesia, rigidity, and activities of daily living deteriorate
faster in the earlier stages of the disease (Maetzler, Liepelt, & Berg, 2009). Furthermore,
cognitive impairments, speech difficulties, sleep problems and gait difficulties develop
throughout the progression of the disease (Maetzler et al., 2009). In the later stages of
the disease, orthostatic dysfunction, visual hallucinations, and variability in heart rate
develop (Maetzler et al., 2009). The life expectancy of patients with PD has been shown
to be lower than the general population (Hobson, Meara, & Ishihara-Paul, 2010). In
patients who do not develop dementia, the survival is shown to be similar to the general
population (Hobson et al., 2010). In other words, patients with dementia and with a
younger onset of PD appear to have shorter life expectancies than other patients with PD
(Hobson et al., 2010).
Gender and Ethnicity
Evidence suggests the prevalence of Parkinson’s disease is higher in the male
population (Cantuti-Castelvetri et al., 2007) with a 60% and 40% male to female ratio.
There is limited evidence regarding the prevalence of PD in ethnic minority groups.
However, current research found PD impacts diverse racial and ethnic groups worldwide
and one-fifth of patients with PD in the United States are from ethnic minority groups
(Schneider, et al., 2009). However, more research needs to be conducted regarding the
prevalence of PD in racial and ethnic minorities.
3

Symptoms
There are several cardinal symptoms associated with PD. The most common and
recognizable feature of PD is a unilateral rest tremor (Shahed & Jankovic, 2007).
Cardinal symptoms of PD include rigidity, akinesia or bradykinesia, postural instability,
flexed posture, and freezing (Jankovic, 2008). In addition, there are several secondary
motor symptoms that are present in patients with PD including the re-emergence of
primitive reflexes and unintended movements accompanying voluntary activity in
homologous muscles (Jankovic, 2008; Thomas, 1994; Li et al., 2007; Wu, Sitburana &
Jankovic, 2007). Neuro-opthalmological abnormalities such as decreased blink rate,
ocular surface irritation, altered tear film, visual hallucinations, blepharospasm and
decreased convergence also occur in individuals with PD (Biousse et al., 2004; Jankovic,
2008). Individuals with PD experience respiratory disturbances, which can be either
restrictive or obstructive (Jankovic, 2008). Non-motor symptoms are present in
individuals with PD. These include autonomic dysfunction, cognitive and
neurobehavioral abnormalities such as dementia sleep disorders, and sensory
abnormalities (Jankovic, 2008). Sensory symptoms include olfactory dysfunction, pain,
paresthesia, akathisia, oral pain, and genital pain (Jankovic, 2008).
Drug Treatment
Pharmacological treatments for PD are tailored to the specific needs and
circumstances of the patient with PD (Schapira, 2005). As a result, treatments can vary
significantly in patients depending on their stage of the disease and response to
pharmacologic treatments. Pharmacological treatments are typically introduced to
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patients with PD when symptoms interfere with daily activities such as work and social
activities (Schapira, 2005).
Currently, pharmacologic treatments primarily focus on improvement of the
motor features associated with PD. Other pharmacologic treatments are used to treat
non-motor symptoms such as depression, anxiety, hallucinations, sleep disorders, sexual
dysfunction, bowel problems and gait, pain, and fatigue given these symptoms can cause
significant distress to patients with PD. There have been several pharmacological
treatments shown to be effective in treating the non-dopaminergic symptoms of PD.
Surgical treatment
Surgical treatments for PD have been taking place for over 100 years (BronteStewart, 2003). New surgical approaches were developed in the early 1990s as a result
of gaining a better understanding of the pathophysiology of PD (Walter & Vitek, 2004).
For instance, there have been significant advances in understanding the basal ganglia
physiology (Bronte-Stewart, 2003). Thalamotomy was an early surgical procedure used
to treat the resting tremor associated with PD. Unfortunately, there were multiple side
effects associated with the procedure including an exacerbation of speech and gait
disorders (Walter & Vitek, 2004). Thalamotomy was not recommended following the
introduction of the pallidotomy procedure and deep brain stimulation (DBS; Walter &
Vitek, 2004). One approach to DBS is the stimulation of the thalamus or the ventral
intermediate nucleus, which has been shown to be effective in reducing the tremor in
patients with PD (Walter & Vitek, 2004). Another DBS procedure that has been
implemented in patients with PD is the stimulation of the internal globus pallidus and
subthalamic nucleus, which has demonstrated improvement in the cardinal motor
5

symptoms associated with PD including akinesia and bradykinesia, rigidity, tremor and
gait (Walter & Vitek, 2004).
Several other surgical procedures (i.e., neural transplantation) have been
implemented in treating patients with PD. There are two types of neural transplantation:
stem cell surgery and fetal tissue surgery. While there have been several surgical
procedures used in treating PD, this study focused on neural transplantation, and more
specifically, fetal tissue transplantation in persons with PD. Fetal tissue transplantation
surgery is the stereotactic implantation of human embryonic dopamine neurons into the
brain (McRae et al., 2004). In 2001, results of a double-blind, sham-surgery-controlled
trial of the implantation of embryonic dopamine neurons in patients with severe PD were
reported (Freed et al., 2001). The goals of the study included determining if the
implanted neurons survived in patients and if the implanted neurons led to a reduction in
symptoms and signs associated with PD. In addition, the study examined the effect of
age on the efficacy of the transplantation of embryonic dopamine neurons. The primary
aim of the study was to determine whether the transplant group improved more than the
participants in the sham group during the double-blind sham-controlled trial (Freed et
al., 2001).
The study found human embryonic dopamine neurons survived in patients with
severe PD and that younger patients received some clinical benefits (Freed et al., 2001).
Along with the neurological investigation of the fetal transplantation surgery trial, there
was a concurrent examination of the quality of life among the participants in the doubleblind, sham surgery-controlled trial.

6

Quality of Life Study
The quality of life (QoL) study was conducted by McRae et al. (2004) in order to
determine whether QoL improved in participants in the transplant group compared to the
sham group following the double-blind, sham surgery-controlled trial. The study was
conducted during the first year of double-blind follow-up and the participants were
assessed at baseline, 4, 8, and 12 months after surgery. The participants’ quality of life
(QoL) was assessed by examining three different domains: physical, emotional and
social functioning. The physical functioning items assessed the patients’ perspectives of
ADL’s, severity of symptoms, and how “free” or “restricted” participants felt “in doing
what you want to do.” The emotional functioning set of items assessed depressive
symptoms, current and situational aspects of anxiety, stress, and degree to which the
chronic illness interferes with usual life activities. The social functioning set of items
assessed aspects of both perceived social support as well as the amount of social
interaction or activity experienced by each participant.
The researchers found very few differences between the transplant and sham
groups at any of the follow-up assessments. Likewise, there were few changes over
time. However, there were a number of significant differences between groups as well as
changes over time based on perceived treatment or type of treatment participants’
thought they received (McRae et al., 2004). Results indicated that those who thought
they received the transplant reported improvements and those who thought they received
the sham surgery reported a worsening of symptoms and outcomes regardless of actual
type surgery they received. As a result, the researchers found the placebo effect greatly
impacted the results of the study.
7

Longitudinal Perspective
As a follow-up to the original QoL study, an investigation of the longitudinal
effects of the transplant among those who participated in the unique double-blind
surgery trial was conducted by Cole (2009). This study solicited information from the
original participants approximately 10-12 years following the transplantation surgery.
The individuals were located and agreed to participate. They completed some of the
original QoL measures as well as the NEO-FFI, a personality inventory (Cole). There
were several significant changes found from baseline to 10-12 years following the
procedure regarding the physical functioning, emotional functioning and social
functioning of QoL (Cole). In addition, significant changes since baseline were found
on the Neuroticism, Extraversion, Openness to experiences, and Conscientiousness
factors of the NEO-FFI (Cole). The study conducted by Cole examined the quantitative
data to explore the impact of this surgical trial on participants over an extended period of
time. However, there has never been an examination of the qualitative aspects of the
participants’ experiences in this study.
Mixed Methods
A mixed methods approach is the integration of multiple forms of data including
both quantitative and qualitative data. More specifically, a mixed method design
incorporates real-life understandings, multi-level perspectives and cultural influences
along with a collection of quantitative data (Creswell, Klassen, Plano Clark & Smith,
2011). There are many strengths in exploring qualitative data, including the ability to
examine different contexts, the meaning of human lives and previously unknown
processes (Creswell et al., 2011). This study was designed to take a mixed methods
8

approach and to integrate the quantitative and qualitative data to use the strengths of
both approaches in examining the longitudinal perspectives of participating in a doubleblind, sham-controlled surgery trial. However, during the data analysis phase of the
study, it became evident that the quantitative data could not be analyzed statistically due
to the small sample size and as a result, a qualitative approach was used as opposed to a
mixed methods approach.

	
  

Statement of the Problem
The research on fetal transplantation in patients with PD is limited. Furthermore,
there is limited research pertaining to long-term effects of participating in a doubleblind-sham-controlled study. While there has been one long-term follow-up
investigation, there has been no qualitative data gathered on the impact of participating
in the fetal transplant surgery trial. This study examined the longitudinal impact on QoL
of participating in the fetal transplantation study conducted by Freed et al. (2001) from
both a qualitative and quantitative perspective. To examine the impact of participating
in the study and the course of the disease, the participants’ QoL including Physical
functioning, Emotional functioning, and Social functioning was assessed along with
Optimism. This qualitative and quantitative investigation provided information that is
possibly valuable to neurologists and scientists interested in developing effective
treatments for PD. The quantitative data explored the current status of the participants
approximately 13-15 years following the fetal transplantation. The qualitative data
provided a glimpse into the personal experiences of the participants and provided a
broader understanding of the impact of participating in this unique double-blind study
and the effectiveness of the experimental procedure.
9

The participants in this study were the surviving participants of the study
conducted by McRae et al. (2004). In the study conducted by Freed et al. (2001), there
were a total of 40 participants admitted to the Irving Center for Clinical Research at
Columbia University for a total of five assessments: two before surgery at baseline, and
at 4, 8 and 12 months following the surgery. To examine the effectiveness of the fetal
tissue transplantation surgery, 20 participants were assigned to the transplant surgery and
20 participants were assigned to receive the sham surgery. The participants assigned to
the sham surgery were given the option to undergo the procedure following revealing of
the double-blind. All of the patients and medical staff who were attending the patients
were blind to the treatment-group assignments throughout the study. The study was
conducted to examine the effectiveness of the fetal tissue transplantation surgery and,
more specifically, to determine if the participants in the treatment group demonstrated
greater improvements than the participants who received the sham surgery.
The QoL study by McRae et al. (2004) was conducted to assess the QoL in the
participants. The researchers assessed the participants’ QoL at baseline, 4, 8 and 12
months following surgery (McRae et al., 2004). A total of 30 out of the 40 participants
in the study by Freed et al. (2001) agreed to participate in the study and in this group
there were 12 participants who received the transplant and 18 participants who received
the sham surgery (McRae et al., 2004). The purpose of the study was to determine if
QoL improved more in the treatment group than in the sham surgery group (McRae et
al., 2004). Furthermore, the researchers investigated whether participants who thought
they received the transplant improved more than the participants who thought they
received the sham surgery.
10

The present study used the quantitative data on QoL gathered in the original
study at baseline, 12 and 24 months after the transplantation and follow-up data gathered
in 2008. The present study involved collecting quantitative and qualitative data
regarding QoL and optimism from the surviving patients who participated in the original
QoL study by McRae et al. (2004). The study assessed longitudinal changes in QoL and
optimism that have taken place over time from both a quantitative and qualitative
perspective.
Research Questions
1. What is the trajectory of change in QoL for all the participants in the current
study from the baseline, 12 and 24 months after transplant, 10-12 follow-up
assessment conducted in 2008 and current 13-15 year follow-up assessment?
Because of the small sample size, no statistical analyses were performed. Instead,
the averages for the participants on each measure were calculated and then
plotted to examine the changes over time. In addition, individual scores on each
of the measures were plotted over time. Thus, a mixed methods approach could
not be used in the current study and as a result, a qualitative approach was used.
2. What are the individual experiences of the participants who participated in the
double-blind sham controlled transplantation study and original QoL study?
3. Would the participants, who participated in original transplantation study,
volunteer to participate in a future double-blind sham-controlled surgical trial?

11

Limitations of the Study
There were several limitations present in the current study. The first limitation
was the small sample size in the current study. The participants include only a small
portion of the participants from the original QoL study (n=30) since several participants
from the original QoL study have died and others have perhaps moved to a different
location or were not able to be found. As a result, their contact information was no
longer valid.
The second limitation was that the data were not generalizable to all patients with
PD. There were strict inclusion and exclusion criteria used in the original transplant
study and, therefore, the current sample does not include patients with PD who may have
other neurological disorders, chronic illnesses, or severe mental health issues.
Additionally, the participants in the current study underwent an experimental surgery,
12-month double blind condition and sham-controlled procedure, and as a result, their
experiences are unique compared to other patients with PD. The participants of the
original transplant study (Freed et al., 2001) and original QoL study (McRae et al., 2004)
volunteered to undergo a experimental surgical trial, which may set them apart from
other patients with PD who may have declined to participate in a surgery trial. Their
experiences are extremely valuable in understanding the impact the original transplant
study has had on their lives and different aspects of QoL.

12

Summary
Chapter One presented an overview of PD, which included the physiology, onset,
symptoms, drug and surgical treatments. A detailed discussion of QoL and mixed
method research design was also presented. Chapter Two provides a detailed review of
the current literature on PD, drug treatments, surgical procedures, QoL and mixed
methods.
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Chapter 2
Literature Review
Introduction
Chapter Two provides a broad overview of PD along with a discussion of
pharmacological treatments, surgical interventions with an emphasis on fetal
transplantation, long-term progression of PD, QoL and mixed methods research.
The literature reviewed in this chapter was retrieved using multiple databases.
The database MEDLINE was used to provide information on history of PD, onset and
prevalence of PD, symptoms of PD, drug treatments, and surgical interventions
including the fetal transplantation surgery. A secondary search was conducted using
multiple databases including PsycINFO, and PsycARTICLES. Topics in the second
search were QoL, mixed methods research and treatment of PD.
Definition of PD
James Parkinson, who wrote the Essay of the Shaking Palsy in 1817, was the first
person to formally discuss the signs of this unusual disorder. Jean Martin Charcot
expanded the early description of PD by separating PD from multiple sclerosis and other
disorders characterized by tremors (Goetz, 2011). Moreover, Charcot recognized the
work of James Parkinson and termed the disorder “Parkinson’s disease” instead of
paralysis agitans (Goetz, 2011). Today, PD is recognized as a progressive neurological
disorder characterized by motor and non-motor symptoms. The motor symptoms
14

include tremor, rigidity, akinesia or bradykinesia, postural instability, fixed posture and
freezing (Jankovic 2008). Non-motor symptoms include autonomic dysfunction
(orthostatic hypotension, sweating dysfunction, sphincter dysfunction, erectile
dysfunction), cognitive and neurobehavioral abnormalities (dementia, affective
disorders, obsessive-compulsive and impulsive behavior), sleep disorders and sensory
abnormalities (Jankovic, 2008).
The etiology of idiopathic PD is still unknown despite PD being the most
common neurodegenerative disorder in elderly populations and representing a
considerable personal and societal burden on individuals with PD and their families
(Rod, Hansen, Schernhammer, & Ritz, 2011). Currently, there is no one technique or
assessment that provides a primary diagnosis of PD. Diagnosis of PD is based on a
detailed record of a patient’s medical history along with a combination of physical and
neurological assessments (Hughes, Daniel, Ben-Shlomo, & Lees, 2002).
Despite the numerous treatment options available to individuals with PD, 40 %
of individuals with PD continue to have motor fluctuations and 28% experience
Levodopa-induced dyskinesias (Shrag & Quinn, 2000). Currently, PD can not be cured;
however, the symptoms of PD can be managed by medications for a number of years.
Symptoms
The three cardinal symptoms of PD are bradykinesia, muscular rigidity and
tremor (Pellicano et al., 2007). Bradykinesia, or slowness of movement, primarily
contributes to the disability associated with PD progression (Pellicano et al., 2007).
Initially, bradykinesia will manifest itself as slow reaction time or planning, initiating,
and executing movement (Berardelli, Rothwell, Thompson, & Hallett, 2001; Jankovic,
15

2008). Muscular rigidity is an increase in resistance among the joints in forming passive
movements. Among individuals with PD, muscular rigidity only minimally contributes
to disability. Tremor is the most commonly associated symptom with PD. Tremors are
the uncontrollable shaking of an upper or lower extremity. Tremors, in persons with
Parkinson’s disease, can be a rhythmic, involuntary, or an oscillating movement of a
body part. Tremors have been shown to worsen as persons with PD focus on the tremor
or become increasingly anxious (Dakof & Mendelsohn, 1986). Rigidity is another
symptom commonly associated with Parkinson’s disease and the presentation of rigidity
often manifests itself as muscle stiffness, cramping or soreness. In persons with PD,
slowness of movement may also result as the motor program retrieval system becomes
impaired, resulting in slowed movements (Marsden, 1989).
In addition to primary symptoms associated with PD, there are multiple
secondary symptoms including constipation, decreased sexual libido, insomnia, hot
flashes or chills, seborrhea, excessive sweating, conjunctivitis and impairment of visual
spatial behaviors (Duvoisin, 1984; Mayeux, 1984). The severity of motor symptoms,
including both primary and secondary symptoms, and nonmotor symptoms can fluctuate
and vary in individuals. However, all three of the primary symptoms, which include
tremors, rigidity and bradykinesia need to be present to make a formal diagnosis of PD
(Duvoisin, 1984).
As a result of the debilitating effects of PD and the progressive nature of the
illness, there are psychological symptoms associated with PD, which include depression,
anxiety, numbness, restlessness, sleep difficulties, fatigue and hypotension (Fahn, 2003).
The rates of psychiatric symptoms have been reported to occur in as many as 87% of PD
16

patients (Kulisevsky, Pagonbarraga, Pascual-Sedano, Garcia-Sanchez, & Gironell,
2008). Depression is the most common psychiatric illness in persons with PD and
clinically significant depressive symptoms are present in approximately 35% of persons
with PD (Reijnders, Ehrt, Weber, Aarsland, & Leentjens, 2008). From the research on
the effects of PD on patients, it is evident that PD impacts every aspect of a person’s life.
Drug Treatment
Dopaminergic drugs are used in treating PD as they have been found to be
effective in improving motor function, reducing morbidity and mortality of PD, and
improving overall quality of life (Clarke, Zobkiw & Gullaksen, 1995; Rajput, 2001;
Schapira, 2005). Levodopa is the most common drug in this classification and
specifically improves bradykinesia and rigidity (Schapira, 2005). Although Levodopa
may be effective for a number of years, its potency is modified due to disease
progression and the loss of the dopaminergic cells needed to metabolize the drug. As a
result, individuals may experience motor complications or a “wearing off” syndrome
(Schapira, 2005). Thus, approximately 80% of patients with PD experience motor
complications after 5-10 years of Levodopa use (Hammod, Bergman & Brown, 2007).
Levodopa may be given in conjunction with a catechol-O-methyltransferase (COMT)
inhibitor, which increases the absorption of Levodopa by reducing O-methylation in the
gut (Schapira, 2005).
Surgical Treatment of PD
In the past 20 years, there has been an emergence of surgical interventions as a
result of the negative effects of the long-term use of Levodopa. Surgical interventions
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used in treating PD include ablative surgery, deep brain stimulation, gene therapy, and
neural transplantation surgery.
Ablative Surgery
Ablative procedures, also known as lesioning procedures, target areas of the
brain that produce tremors (Ahmed, Sheraz, & Ahmad, 2010). In ablative procedures,
surgeons create small lesions using high frequency electric currents (Ahmed et al.,
2010). There are three types of ablative surgery: thalamotomy, pallidotomy, and
subthalamotomy. Thalamotomy is a surgical procedure where the ventral intermediate
nucleus is targeted (Walter & Vitek, 2004). Previous research has found the lesions in
the ventral intermediate nucleus improve tremors (Ahmed et al., 2010). Patients with
asymmetric, severe and medically intractable tremor are recommended to have a
thalamotomy (Ahmed et al., 2010). There are several adverse effects as a result of
undergoing a thalamotomy, which include paresthesias, motor weakness, dysarthria,
disequilibrium and gait disturbance. Bilateral thalamotomy may be conducted on
patients with bilateral symptoms; however, there is an increased risk of speech and
cognitive difficulties associated with bilateral thalamotomy procedures.
Pallidotomy is another type of ablative surgery where parts of the globus pallidus
(GPi), are destroyed (Ahmed et al., 2010). The GPi region of the brain controls
movements to restore balance (Ahmed et al., 2010). There have been two single-blind
randomized trials completed to compare unilateral pallidotomy with drug treatments. In
the first study with a sample of 37 patients, Unified Parkinson’s Disease Rating Scale
(UPDRS) “off” motor scores showed a 31% improvement from the baseline (Walter &
Vitek, 2004; de Bie et al., 1999). A second study involving 36 patients with PD was
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conducted and researchers found 32% improvement on the “off” motor UPDRS motor
score, which was assessed at 6 months from the baseline (Walter & Vitek, 2004;Vitek et
al., 2003). Overall, unilateral pallidotomy has been shown to improve drug induced
dyskinesia, bradykinesia, rigidity and tremor (Ahmed et al., 2010). However, the
benefits of unilateral pallidotomy vary in long-term follow-ups (Ahmed et al., 2010).
The third type of ablative surgery is subthalamotomy, which has received less
attention than thalamotomy and pallidotomy. Subthalamotomy targets the subthalamic
nucleus in the brain. While there have been improvements in patients with PD who have
undergone a subthalamotomy procedure, surgeons fear performing the procedure due to
the risk intractable hemiballism (Walter & Vitek, 2004). However, research has shown
subthalamotomy can be completed without concerns of hemichorea. Studies on
subthalamotomy showed 15-50% improvement in the “off” medicine UPDRS motor
score at a two-year follow- up (Walter & Vitek, 2004). In addition, bilateral
subthalamotomy has demonstrated fewer speech and cognitive side effects compared to
bilateral pallidotomy or thalamotomy (Walter & Vitek, 2004).
Deep Brain Stimulation
Deep brain stimulation (DBS) is a widely popular therapeutic treatment for PD
and has been subject to a significant amount of research. DBS is a surgical technique
where continuous electrical stimulation is delivered through implanted electrodes
connected to an internalized neuropacemaker (Benabid, 2003). Multiple deep brain
structures have emerged as potential therapeutic targets in treating PD (Collins,
Lehmann, & Patil, 2009). Research in the 1990s and early 2000s suggested the ventral
intermediate nucleus (VIM) of the thalamus was the target for DBS therapy in treating
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the tremors associated with PD (Collins et al., 2009). However, targeting the VIM in
DBS has been shown to have little impact on the other common symptoms associated
with PD including rigidity and bradykinesia (Collins et al., 2009). As a result, DBS
targeting the VIM is useful in a small percentage of patients where tremors are the
predominant symptom. Another area targeted in DBS is the internal globus pallidus
(GPi), which has been shown to be effective in treating tremors while also decreasing
symptoms of dyskinesia, rigidity and bradykinesia and improving postural stability
(Collins et al., 2009; Obeso et al., 2001). Additionally, stimulation of the subthalamic
nucleus (STN) is effective for the treatment of rigidity, bradykinesia, and tremor. One
study examining the effectiveness of STN stimulation for PD demonstrated
improvements of 50% in UPDRS motor scores, with improvements having been
observed for periods of 5 years (Krack et al., 2003). In addition, STN DBS allows
patients with PD to have a 50% to 60% reduction in dopaminergic agent dosage, which
may lead to an improvement in dyskinesias due to Levodopa (Hamani, Richter, Schwalb,
& Lozano, 2005; Kleiner-Fisman, Herzog, Fisman, Tamma, Lyons et al., 2006).
A randomized controlled trial of DBS therapy for PD by Weaver et al. (2009)
showed patients with PD receiving STN DBS or GPi DBS showed 4 or more hours of
additional “on” time per day without the side effect of dyskinesia. Additionally, the
“off” time and “on” time with dyskinesias was reduced compared to pre-operative
baseline (Weaver et al., 2009).
Gene Therapy
Gene therapy is a promising new experimental treatment for persons with PD.
Hopefully it will offer patients an alternative treatment to pharmacologic and surgical
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interventions. Gene therapy in patients with PD uses viral vectors to carry out gene
transfer (Rodnitzky, 2012). As a result, there is targeted protein expression in different
areas of the brain (Rodnitzky, 2012). There are multiple types of gene therapy: AAVGAD gene therapy in the subthalamic nucleus (SN), AAv2-Neurturin gene therapy
(CERE-120), Aromatic L-amino acid decarboxylase (AADC) gene therapy, and prosavin
(Rodnitzky, 2012). At this point, it is still continuing to undergo human clinical trials.
While gene therapy has shown promise, it has not yet been shown to be superior to
surgical or pharmacologic treatments for patients with PD.
Neural Transplantation
An additional experimental treatment for patients with PD is the stereotactic
implantation of human embryonic dopamine neurons into the brain (Freed et al., 2001;
McRae et al., 2004). Current neural transplantation procedures include stem cell
transplantation surgery and fetal tissue transplantation surgery.
Neural Transplantation: Stem Cell Transplantation Surgery
The transplantation of stem cells into the brain has been a procedure used in
treating neurogenerative diseases including PD. The ability for stem cells to
differentiate into multiple cells types or all cells of the body makes them beneficial for
transplantation (Lindvall, Kokaia, & Martinez-Serrano, 2004). The transplantation of
stem cells into the brain has been shown to be possible in several clinical studies (Politis
& Lindvall, 2012). Given that PD is the degeneration of nigrostiatal dopaminergic
neurons, the transplantation of human fetal mesencephalic tissue, which is rich in
postmitotic dopaminergic neurons, has been shown to be effective in neuronal
replacement in the brain (Lindvall et al., 2004). The grafted neurons survive and
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reinnervate the striatum for approximately 10 years (Kordower et al., 1995; Piccini et al.,
1999). Additionally, the grafted neurons have been shown to normalize striatal
dopamine release and reverse the progression of the cortical activation underlying
akinesia (Lindvall et al., 2004; Piccini et al. 2000; Piccini et al., 1999). As a result, the
grafted dopaminergic neurons can be incorporated into the neuronal circuitries in the
brain (Lindvall et al., 2004; Piccini et al., 2000).
The results of the stem cell transplantation surgery, however, are mixed (Politis
& Lindvall, 2012). One reason for modest effects is the limited amount of surviving
grafted dopaminergic neurons (Lindvall et al., 2004). Research also has yet to show that
the stem cells can “provide efficient functional reinnervation and behavioral recovery in
animal PD models” (Lindvall & Kokaia, 2009). In addition, dyskinesias have been
shown to develop following the transplantation, which are believed to result from
uneven or patchy reinnervation (Lindvall et al., 2004). More research needs to be
conducted on the efficacy of stem cell transplantation in patients with PD. Future
research studies will need to “require better criteria for patient selection, improved
functional efficacy for grafts by a tailor-made transplantation procedure providing
optimum repair of the patient’s DA system and strategies to prevent dyskinesias and
tumor formation” (Lindvall & Kokaia, 2009).
Neural Transplantation: Fetal Tissue Transplantation Surgery
Fetal transplantation surgery has been investigated over the last several decades.
Fetal transplantation surgery began in 1980’s and 1990’s when human fetal
mesencephalic tissue was transplanted in the striatum in patients with PD (Lindvall &
Bjorklund, 2004). The initial procedures performed in 1987 demonstrated that cell
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replacement works in the human brains of patients with PD (Bjorklund et al., 2003;
Lindvall & Bjorklund, 2004). Moreover, the early trials demonstrated human fetal
dopaminergic neurons can survive and function in the striatrum of patients with PD for
more than10 years (Bjorklund et al., 2003). Following the initial trials of fetal
transplantation in humans, the National Institutes of Health (NIH) supported additional
efforts to investigate fetal transplantation in patients with PD (Bjorklund et al., 2003).
As a result, two double-blind sham-surgery controlled trials were investigated in the
1990’s (Bjorklund et al., 2003).
Freed et al. (2001) completed a double-blind, sham surgery controlled trial to
examine if the transplant group improved compared to the sham group. The
investigators also explored whether the implanted cells survived in the patients who
underwent the transplantation surgery and the efficacy of the transplantation on physical
symptoms associated with PD (Freed et al., 2001). Additionally, the investigators
determined if age was a factor in the efficacy of the transplantation procedure (Freed et
al., 2001).
The investigators randomly assigned 40 patients with severe PD to undergo the
transplantation of neural cells or a sham surgery; 20 participants received the transplant
and 20 participants received the sham surgery (Freed et al., 2001). The participants
ranged in age from 34 to 75-years of age and all of the participants were found to have
had at least two of the three cardinal symptoms for more than seven years (Freed et al.,
2001). The patients were awake during the procedure and given local anesthesia (Freed
et al., 2001). The transplantation procedures included a stereotactic ring being affixed to
the skull before imaging was conducted to define placement for passes in the axial plane
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of the putamen with two needle tracks on each side of the brain. During surgery, four
burr holes were made in the patients’ forehead and cultured mesencephalic tissue from
four embryos was transplanted into the putamen bilaterally (Freed et al., 2001). In the
sham surgery, the patients underwent an identical procedure, including drilling holes in
the forehead. However, the dura matter was not penetrated and the cultured fetal tissue
was not placed in the brain (Freed et al., 2001). All of the fetal transplantation
procedures were performed at the University of Colorado Hospital (Freed et al., 2001).
Results showed human embryonic dopamine-neuron transplants survived in all patients
and there were some clinical benefits in younger participants (Freed et al., 2001). More
detailed information regarding the parent study and the fetal transplantation surgery can
be found in the report by Freed et al. (2001). The present study will be a longitudinal
follow-up of individuals who participated in the study conducted by Freed et al (2001).
An additional double-blind sham-surgery trial was undertaken by Olanow et al.
(2003). The study was a 24-month double-blind, placebo controlled trail of fetal nigral
transplantation in 34 patients with advanced Parkinson’s disease (Olanow et al., 2003).
The participating patients with PD received bilateral transplantation with one or four
donors per side or a placebo procedure (Olanow et al., 2003). Following the completion
of the study, patients showed no significant overall treatment effect. However, patients
with milder symptoms of PD at the baseline showed significant improvements (Olanow
et al., 2003).
These trials exhibited variable results. Despite several open label trials that
showed improvements in striatal uptake of fluorine-18-labelled dopa and UPDRS motor
scores, the results have been mixed amongst patients with PD (Bjorklund et al., 2003).
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One reason for the varied results in patients with PD is the differences in the survival
and growth of the grafted dopaminergic neurons in patients. In addition, the placebo
effect may play a stronger role in the results than originally thought.
Original QoL Study
A total of 30 participants out of the 40 from the fetal transplantation study agreed
to participate in the QoL study conducted by McRae et al. (2004). The QoL study
examined the QoL and medical outcomes of the 30 patients (12 patients who received
the transplant and 18 patients who received the sham surgery) at four, eight and twelve
months before the double-blind was lifted. The researchers found only one statistically
significant difference between the two treatment groups at baseline, 4, 8, and 12 months.
However, based on perceived treatment or the type of surgery patients’ thought they
received, researchers found multiple differences in QoL outcomes. For instance, at the
12-month follow-up, participants who thought they received the transplant reported more
positive results regarding physical functioning compared to the participants who thought
they received the sham surgery, regardless of the actual type of surgery they received
(McRae et al., 2004). The results of this study illustrate the impact of the placebo effect
on the fetal transplantation surgery trial.
Longitudinal Follow-up at 10-12 Years After Original Study
Cole investigated the long-term effects of the fetal transplantation surgery on
QoL factors on the participants from the parent study (Cole, 2009). A total of 11
participants agreed to participate in the longitudinal follow-up study (Cole, 2009). The
patients’ physical, emotional and social functioning were assessed and compared to the
baseline, one-year and two-year data after transplantation obtained in the original QoL
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study conducted by McRae et al. (2004). All participants in the longitudinal follow-up
study had received the transplant, either originally or after the blind was revealed and
they were allowed to receive the transplant after first being given the sham surgery.
The results from the study showed participants reported improvements in
physical functioning between baseline and the two-year follow-up (Cole, 2009). More
specifically, the majority of the participants experienced improvements in physical
functioning from baseline to the one-year assessment. Following the two-year followup, however, participants reported a decline in physical functioning (Cole, 2009).
Regarding emotional functioning in the participants, the results showed improvements in
emotional functioning between the baseline and two-year follow-up (Cole, 2009).
During the two-year assessment and 10-12-year follow-up, however, there was a decline
in emotional functioning, which was consistent with physical functioning (Cole, 2009).
Social support decreased between baseline and one-year assessment but showed
improvements at the two-year assessment (Cole, 2009). Additionally, social support
decreased significantly between the two-year assessment and the 10-12-year follow-up
(Cole, 2009).
Quality of Life
The exploration of QoL in patients with PD has been researched in recent
decades to determine effective treatments in reducing both the motor and non-motor
symptoms associated with PD. QoL gives researchers insight into the individual
experiences of the patients with PD and the impact of specific treatments on the patients’
everyday functioning. In addition, the medical field and medical professionals have
begun to look beyond treating only the physical symptoms associated with PD and as a
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result, they are beginning to take a multi-dimensional approach to treating patients. In
other words, medical professionals are now recognizing the significant impact of nonmotor symptoms such as cognitive impairments, sleep problems, dementia and
depression on patients with PD. In developing treatments directed at treating both the
motor and non-motor symptoms of PD, one of the goals is to improve quality of life.
There are several definitions that exist regarding QoL. Felce and Perry (1995)
described QoL as an integration of objective and subjective factors that incorporates a
wide range of life domains and individual values (Felce & Perry, 1995). Quality of life
(QoL), according to the study conducted by McRae et al., includes three dimensions:
Physical, Emotional and Social functioning (2004). WHO defined QoL as ‘an
individual’s perception of his/her position in life in the context of the culture and value
systems in which he/she lives and in relation to his/her goals, expectation, standards and
concerns (Ferrara et al., 2010; WHOQOL Group, 1995, p. 1405). Researchers have also
used the concepts of health related quality of life (HRQoL) and health status (HS) to
examine the benefits of treatments. These concepts have been developed to encompass
the impact of a health condition on overall functioning. However, there are no current
universal definitions for HRQoL and HS (Ferrara et al., 2010). HS measures focus on
the presence of symptoms and their impact on an individual’s ability to perform various
daily activities such as leisure activities and housework (Ferrara et al., 2010). In
contrast, HRQoL measures explore a patient’s subjective experiences of symptoms and
satisfaction with their health condition (Ferrara et al., 2010).
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Quality of Life: Importance of the Patient’s View in clinical trials
As mentioned previously, the majority of the past research conducted regarding
treatments of PD has focused on the medical perspective and the treatment of the
physical symptoms of the disease. In recent years, however, research has begun to
explore the perspectives of the patients’ with PD to gain an understanding of the impact
of the disease on the lives of the patients.
One study conducted by Politis et al. (2010), examined the patients’ perspectives
regarding the symptoms associated with PD. The researchers had the patients rank their
three most troublesome symptoms in the last six months (Politis et al., 2010). The
results from the study demonstrated diversity in the experiences and perspectives of
patients with PD. The study found the lack of response of medication and non-motor
symptoms were the most troublesome issues (Politis et al., 2010). The study
demonstrated the importance of examining the perspective of the patient with PD to treat
both the motor and non-motor symptoms associated with PD (Politis et al., 2010).
Moreover, the study conducted by Politis et al. emphasizes the importance of exploring
patient’s experiences and perspectives to aid in developing patient-centered care and
management (Politis et al., 2010).
One method of assessing patients’ perspectives is to use QoL as a measure. QoL
explores the physical functioning, psychological/emotional functioning, social
interaction with others/social support in patients with PD. The assessment of QoL
explores a patient’s personal experiences and beliefs regarding the progression of the
disease and the impact on different domains of daily life. The exploration of QoL in
patients with PD allows medical providers to gain a holistic view of how the patients are
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functioning and coping with the disease. In taking a more holistic view of patients’
functioning, more effective treatments can be developed and designed to address both
the motor and non-motor symptoms associated with PD.
One study examined factors that determine QoL in patients with idiopathic PD.
Schrag, Jahanshahi and Quinn (2000) examined the impact of PD on QoL in 124 patients
with PD using a QoL battery including EuroQoL 5D, the Medical Outcome Study Short
Form (SF 36) and the 39-item Parkinson’s Disease questionnaire (PDQ-39). In addition,
an interview and complete neurologic examination were completed. QoL declined
significantly with the progression of the disease and increase in disease severity (Schrag
et al., 2000). Physical and social functioning demonstrated the greatest decline (Schrag
et al., 2000). Emotional functioning showed results similar to the general population
(Schrag et al., 2000).
Given the progression of PD and the chronic nature of the disease, it is essential
to explore the patient’s perspectives and QoL over a longer period of time to determine
the effectiveness of treatments. One study by Karlsen, Tandberg, Arsland & Larsen
(2000) examined change in QoL in patients with PD across a four-year follow-up from a
community-based 1993 prevalence sample (Karlsen et al., 2000). The results of the
study found increased distress during the four-year follow-up period, and increased
stress correlated with increased parkinsonism as measured by UPDRS and Hoehn and
Yahr stage. Furthermore, pain, social isolation, and emotional reactions in addition to
physical mobility were correlated with increased stress (Karlsen et al., 2000). The study
demonstrated the importance of examining the long-term effects of the disease on the
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QoL of patients and how these findings may assist in targeting and treating distressing
symptoms associated with PD that develop over time.
Assessing QoL in the patients in the parent study illuminates the long-term
effects of participating in a surgery trial on physical, emotional and social functioning in
patients with PD (Cole, 2009). More specifically, continued assessment of QoL in the
patients in the parent study could illustrate the long-term impact of neural transplantation
on the patients’ physical health, severity of symptoms, description of feelings, affective
functioning, stress level, social support and interaction with others.
Important Patient Data on Quality of Life
The investigation regarding how QoL has improved, worsened or stayed the
same in individuals who underwent the neural transplantation surgery is important. The
present study examined the changes in QoL over time from baseline to the current
assessment, including one and two years after the transplant surgery, 10-12 years after
the transplant surgery in 2008 and the current assessment. The purpose of this study was
to examine the long-term effectiveness of fetal transplantation surgery on QoL or
patients’ physical, emotional and social functioning.
Mixed Methods Approach
To examine the perspectives of the patients who participated in the parent study,
a mixed methods approach was used. This topic warrants a qualitative perspective given
the importance of understanding the patient’s perspectives and personal experiences.
Moreover, qualitative research should be conducted when a complex and detailed
understanding is warranted (Creswell, 2007). In this study, QoL was assessed in the 13-

30

15 year follow-up using both quantitative information as well as interviews with the
participants.
The concept of mixing different research methods was originated in 1959 by
Campbell and Fiske who used mixed methods to study the validity of psychological
traits (Creswell, 2007). Following their research study, researchers began combining
traditional quantitative surveys with observations and interviews (Creswell, 2007).
Researchers also argued that there were inherent biases in using a single method
(Creswell, 2007). As a result, the term triangulation was created to describe the
convergence of qualitative and quantitative methods (Creswell, 2007). Following the
initial exploration of using mixed methods, writers began developing specific procedures
for conducting a mixed methods approach to research including multimethod,
convergence, integrated and combined approaches (Creswell, 1994; 2007).
Today, there are multiple types of mixed method approaches used in research.
However, given the quantitative data could not be analyzed statistically, a qualitative
approach was used as opposed to a mixed methods approach. The means scores on the
measures for the participants will be connected with the data gathered from the
interviews when possible.
Summary
Chapter Two provided a literature review on detailed information on PD,
pharmacological treatments, surgical treatments, fetal tissue transplantation surgery,
QoL, long-term follow-up, importance of patient views in clinical trials and mixed
methods approach.

31

PD impacts every aspect of a patient’s life. There is a significant amount of
research regarding PD and treatments for PD; however, there is a limited amount of
research on the QoL of patients with PD from both a longitudinal and mixed methods
approach. In addition, there is limited information on the QoL of patients who
underwent a fetal transplantation surgery trial.
The present study examined QoL in participants who received the fetal tissue
transplantation surgery in the parent study approximately 13-15 years ago. The study
also examined how the physical, emotional and social functioning changed in the
patients over time and from both a quantitative and qualitative perspective. Chapter
Three outlines the methods and procedures used in this study.
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Chapter Three
Methods
Chapter Three describes the methodology used in the present study, including
information on the participants, measures, and data analyses.
Participants in Parent Parkinson’s Disease Study
In the parent study, participants were recruited through neurologists from the
United States and Canada. A total of 40 patients were accepted into the study. Each
participant was evaluated two times for approximately three to four days before being
accepted into the study. A total of 20 participants received the transplant and 20
participants received the sham surgery.
Participants in Original Quality of Life Study
A total of 30 participants from the parent study agreed to participate in the
concurrent QoL study. Of the 30 participants, 12 originally received the transplant and
18 received the sham surgery (McRae et al., 2004).
Participants in the Longitudinal Follow-up at 10-12 Years After Original Study
A total of 14 participants from the original QoL study were able to be contacted
and 11 patients agreed to participate in the longitudinal follow-up study at 10-12 years
following the original surgery. In the current investigation, patients who participated in
the longitudinal follow-up at 10-12 years were contacted and asked to participate in the
present study.
33

Participants in the current study
In the parent study, there were a total of 40 patients in the parent study and 30 of
the participants agreed to participate in the original QoL study. Of the 30 participants
from the original study, updated contact information was identified for 7 people. For the
remaining participants, either contact information was unable to be found, or some
participants had passed away. Of the 7 participants, 5 of them agreed to participate in
the current investigation. For the demographic variables of age, gender, ethnicity,
duration of disease, and level of education, data were collected from the baseline
assessment. For the demographic variables of current living situation, marital status,
currently paid for employment, and volunteer work, data were collected from the current
assessment.
Inclusion and Exclusion Criteria
Several inclusion criteria had to be met in order to participate in the parent study.
The participants were required to be in an advanced stage of idiopathic PD for seven
years or longer and needed to demonstrate some responsiveness to L-dopa. All the
participants had experienced a reduction in the effectiveness of the L-dopa treatment in
addressing their symptoms. Patients have all tried alternative forms of treatment and
needed to be medically appropriate for the transplant surgery, including a certification by
their attending physician. Patients needed to demonstrate symptoms that were chronic in
nature. In other words, the patients needed to show symptoms, including “off” periods
and dyskinesias or freezing, which could not be attributed to dopamine agonists. The
participants funded expenses not covered by the initial NIH grant for the parent studies.
Furthermore, participants could not be diagnosed with depression or report experiencing
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hallucinations. In terms of neurocognitive functioning, the patients were required to
have a normal MRI scans within the last 18 months of the start of the parent study and
undergo a thorough neuropsychological examination (Freed et al., 2001). The
participants underwent a fluorodopa PET, which indicated idiopathic PD (Freed et al.,
2001). The 40 participants all ranged in age from 34 to 75.
The exclusion criteria for the parent study included: severe or moderately severe
depression, gross signs of dementia, previous brain surgery or injury, diabetes, severe
cardiopulmonary disease, other severe medical conditions, and MRI evidence of
cerebrovascular disease (Freed et al., 2001). In addition, patients who did not receive a
medical clearance from their attending physician were unable to participant in the study
(Freed et al., 2001).
Procedure
All of the participants in the original QoL study and longitudinal follow-up 10-12
years following the transplant were contacted in order to request their participation in the
current study. The contact information, including phone number and current address,
was updated via the Internet. Participants were contacted by the researcher via the
telephone to discuss the current study and to assess their willingness to participate in the
current study. Participants were requested to complete questionnaires delivered in the
mail and complete one phone interview. The questionnaires obtained updated
information on PD, QoL and Optimism. The phone interview questions were developed
to assess the patients’ qualitative perspectives on PD, QoL and participating in the
original study.

35

Questionnaires
The questionnaires used in this study were a reduced version of the same
questionnaires sent in the original study by McRae et al. (2004). They were sent to the
participants in the mail and included instruments to assess QoL while living with PD.
Of note, the State-Trait Anxiety Inventory (STAI-State) was not included in the current
questionnaire. As a result, the composite variable of Emotional functioning could not be
created and the three measures of depression, intrusiveness of illness and stress were
analyzed independently. The three measures of Physical Functioning were also analyzed
independently. Interview questionnaires were developed to assess the participants’
perspectives on participating in a double-blind, sham controlled surgery trial and to
assess the impact of the transplant on their lives over time. The questions were
developed to assess the participants’ individual experiences and perspectives and were
administered in one phone conversation. The interview consisted of six questions,
which did not overwhelm the participants and allowed adequate time to discuss each
question thoroughly. Participants were encouraged to expand upon their answers if they
chose to do so.
Measures
The measures can be found in the Appendices B through J. The quantitative
measures described below were sent to the participants in the mail to be completed and
returned to the investigator. The qualitative interviews were conducted over the phone
by this investigator after an introduction by her advisor, Dr. Cynthia McRae, who has
known the participants for over 15 years.
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Physical Functioning
The participants’ level of physical functioning was assessed using the patient
version of the Unified Parkinson’s Disease Rating Scale (UPDRS) developed by
Montgomery, Lieberman, Singh, and Fries (1994). The original UPDRS was developed
for use by medical personnel to assess the physical capabilities of persons with PD. The
patient version of the UPDRS was designed to allow patients to subjectively rate their
level of physical functioning and difficulties related to PD (Montgomery, Lieberman,
Singh, & Fries, 1994). The patient version used in this study is comprised of two scales,
which include Activities of Daily Living (ADLs) at “Worst” (when patients are
functioning physically at their “worst”) and Severity of Symptoms at “Worst.” The
Activities of Daily Living subscale is comprised of eight items, which is scored on a
Likert scale ranging from 1) Normal, 2) Adequate, 3) Limited, 4) Need Help, to 5)
Unable to do. The total score ranges from 8 to 40 points where higher scores are
indicative of a lower level of physical functioning and lower scores are indicative of
better functioning. The activities assessed on the scale include writing, talking, walking,
dressing, hygiene, getting up from a chair, turning in bed, and cutting food.
The Severity of Symptoms Scale is comprised of five items and patients rated
each problem at “Worst” functioning. The rating for each item ranges from 1) Normal,
2) Mild, 3) Moderate, 4) Severe, to 5) Very Severe. The total score can range from 5 to
25 with higher scores indicating poor physical functioning and lower scores indicating
better physical functioning. The symptoms listed on the scale include: tremor,
swallowing, salivation, “freezing” when walking, and falling.

37

Internal consistency reliability of the subscales of the patient version of the
UPDRS ranged from .65 to .90 (McRae et al., 2004). The original UPDRS has
demonstrated adequate construct validity across several widely used measures of
physical functioning in PD (Ramaker, Marinus, Stiggelbout, & van Hilten, 2002).
An additional scale, the Free or Restricted Scale, was used to assess physical
functioning of QoL. The Free or Restricted Scale is a single, global measure that
examines how free or restricted the person feels “in doing what you want to.” The item
is rated using a Likert-type scale ranging from 1 (I still do everything I want to do) to 7
(I can no long do the things I want to do). Higher scores indicate lower physical
functioning and lower scores indicate better physical functioning.
Emotional Functioning
Several assessments were used to determine the emotional functioning of the
participants. The Parkinson’s Disease (PD) Stress Scale was the measure used to assess
stress in the participants. The Parkinson’s Disease Stress Scale has a total of 19 items
and patients are asked to indicate “yes” or “no” on each item. A sample question is “I
am sometimes embarrassed in public because of my symptoms.” The estimated
reliability (Cronbach’s alpha) for the scale was .77 (McRae et al., 2004).
The participants in the study were assessed for depressive affect using the Center
for Epidemiologic Studies Depression Scale (CESD; Radloff, 1977). The scale has a
total of 20- items used to assess the number and frequency of self- reported symptoms of
depression. Each item is rated using a 4-point scale, which ranges from 0 to 3 where 0
indicates “less than 1 day” and 3 indicates “5 to 7 days” (Radloff, 1977). Lower scores
indicate fewer depressive symptoms and higher scores indicate more depressive
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symptoms (Radloff, 1977). A sample item is “I had trouble keeping my mind on what I
was doing.” On the CESD, a total score can range from 0 to 60. Scores on the CESD
have been shown to have an internal consistency of .89 and test-retest reliability has
been found to be satisfactory (Radloff, 1977). Radloff reported the CESD scores have
very good concurrent validity according to clinical and self-report criteria and substantial
evidence of construct validity. Craig, Richardson, Pass, and Bregman (1985) reported a
convergent validity correlation of 0.65, which the researchers compared to Hamilton
Rating Scale for Depression. The CESD assesses depressive symptoms and is not used
as a tool to diagnose depression.
To assess the degree to which Parkinson’s disease interferes with daily living, the
participants completed the Intrusiveness of Illness Scale. The Intrusiveness of Illness
Scale is important in this study since illness intrusiveness is a common underlying
determinant of quality of life in patients suffering from a chronic illness (Devins, 2010).
The Intrusiveness of Illness Scale is a 15-item self-report questionnaire, which measures
the impact of an illness on daily living (Devins et al., 1984). The self-report responses
presented on a Likert-type scale range from 1 (very little) to 7 (a great deal). A total
score on the assessment can range from 15 to 105 (Devins et al., 1984). Total scores in
the high range indicate more intrusiveness and total scores in the low range indicate less
intrusiveness. One example of an individual item is “my illness interferes with my
ability to work.”
The internal consistency reliability has been evaluated for the Intrusiveness of
Illness Scale and research has shown internal consistency reliability ranging from .80 to
.88 (Devins et al., 1984; McRae et al., 2004). Furthermore, test-retest reliability has
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been shown to be high when participants who experience changes in their illness or
treatment have been excluded (Devins et al., 1984; McRae et al., 2004). The assessment
has been shown to have adequate construct validity amongst groups of participants with
a variety of chronic illnesses.
Social Functioning
The Social Provisions Scale (Cutrona & Russell, 1987) assesses social
functioning and perceived degree to which participants’ social relationships might
provide multiple dimensions of social support. The Social Provisions Scale is a 24-item
scale and contains a total of 4 items for each of the following subscales: guidance,
reliable alliance, attachment, social integration, reassurance of worth, and opportunity to
provide nurturance (Cutrona & Russell, 1987). The individual items use a Likert-type
scale ranging from 1 (strongly disagree) to 4 (strongly agree) with higher scores
indicating more perceived social support. The total score can range from 24 to 96. An
example item from the Social Provisions Scale is “I have relationships where my
competence and skills are recognized.”
Cutrona, Russell and Rose (1984) evaluated internal consistency and test-retest
reliability of the Social Provisions Scale and found internal consistency to be above .70
across all provisions amongst a sample of 100 elderly subjects. Furthermore, Cutrona et
al. found reliability to be .91 for the total score on the Social Provisions Scale.
Optimism
To assess Optimism in the participants, the Life Orientation Test (LOT) scale
was administered. The LOT (Scheier & Carver, 1985) assesses dispositional optimism,
which is defined as “a continuum in which pessimism and optimism are polar opposites”
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(Scheier & Carver, 1985). Optimism is the tendency to view the world and situations in
a positive manner. Several research studies have found that optimism is related to
“adequate adjustment to difficult life circumstances in a large number of behavioral
contexts (Carver, Scheier, Miller & Fulford, 2009; Chiesi, Galli, Primi, Borgi &
Bonacchi, 2013). The LOT is an eight-item measure plus four filler items that is
“designed to assess generalized expectations for positive versus negative outcomes
(Vassar & Bradley, 2010). The LOT is measured on a 5-point scale ranging from 0
(strongly disagree) to 4 (strongly agree); (Vassar & Bradley, 2010). In order to get a
total score, negative items are reverse coded and then added to the total score that ranges
from 0 to 32. Higher scores are indicative of greater optimism. According to Scheier
and Carver (1985), the LOT has a coefficient alpha estimate of .82 (Vassar & Bradley,
2010). In addition, the LOT was found to have a test-retest correlation of .79 and
adequate convergent and discriminate validity (Scheier & Carver, 1985).
Data Analyses
The data analyses in the current study were completed in two stages: preliminary
analyses and the primary analyses, which included the quantitative and qualitative data.
The preliminary analyses included an investigation of the demographic information and
descriptive statistics.
For the primary analysis of the quantitative data, it was anticipated that a
repeated measures ANOVA would be used. Unfortunately, all five of the participants in
the current study did not complete assessments at all the different time points.
Therefore, it was not possible to do the intended primary analysis. For instance, one
participant did not participate in 2008 assessment and there was one participant who did
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not complete the quantitative questionnaire in the current assessment. In addition, by 24
months after the surgery for those who initially had the sham surgery, data collection had
essentially stopped and two participants did not complete the questionnaire. In the
current study, averages were calculated and plotted over the last 13-15 years to explore
the changes over time. In addition, each participant’s score for each measure for all the
time points were plotted to examine the changes over time for each participant.
For the primary analysis of the qualitative data, there were 6 questions in the
interview, which are presented below.
Qualitative Questions
1. How do you feel when you reflect back on your experiences in participating in the
fetal tissue surgery trial?
2. Have your feelings regarding your participation in the surgery trial changed over time?

3. Knowing what you know now, would you volunteer to participate in this study again?
Why or why not?
4. What was the most positive aspect of participating in the study?

5. What was the most negative aspect of participating in the study?

6. What advice would you give to future participants in terms of coping with
participating in a double blind placebo surgery trial?
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The qualitative interview questions were designed to gain insight into the specific
experiences of the participants during their participation in a unique surgery trial. It was
important to further explore their personal experiences to better understand why some
participants appeared to be doing better than what would be expected given the
progression of their PD and in contrast to other participants who had not done as well.
In addition, it was helpful to understand what went well in the transplant surgery trial
and what did not go well for these participants in order to provide detailed information to
future researchers conducting a double-blind, sham controlled surgery trial with patients
with PD. The information gathered in the qualitative interview was developed into a
narrative for each participant to outline their responses to each question and provide a
detailed presentation of their overall experience in the transplant surgery trial over the
last 13-15 years.
In a mixed methods approach, there is an attempt to connect several forms of
data. However, given the quantitative data could not be statistically analyzed given the
small sample size, a qualitative approach was used as opposed to a mixed methods
approach. As a result, the plotted changes over time in this study will be integrated with
the qualitative data, which explored individual perspectives of the participants. The
qualitative data was collected in order to provide a richer, fuller picture of the
phenomenon than either approach could provide alone. The plotted results of the
quantitative data were followed by qualitative information (i.e., narratives of
participants) that added depth and meaning to the quantitative results. In addition, the
research questions related to the qualitative information were answered by analyzing the
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responses on the qualitative interview and providing these results in both the Results and
Discussion section.
Summary
Chapter Three outlined the methodology used in the current study. More
specifically, a description of the participants, procedures, QoL measures, and data
analyses were provided. Chapter Four presents the preliminary and primary results of
the current study.
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Chapter Four
Results of the Study
Overview
This chapter presents the results of both the quantitative and qualitative data
aspects of the current study. First, the preliminary analyses are reviewed and then the
results of the primary analyses are reviewed in the context of the research questions. All
the preliminary statistical analyses were performed using the Statistical Package for the
Social Sciences version 20.0 (SPSS 20.0).
Participants of the current study originally represented two treatment groups;
those who initially received the fetal tissue transplant (n=2) and those who initially
received the sham surgery (n=3) and then later received the fetal tissue transplant in the
parent study (Freed et al., 2001). The primary analyses in the current study examined
several domains of QoL and Optimism of participants at baseline, 12, and 24 months
after the fetal tissue transplant, along with data from the10-12 year follow-up assessment
in 2008 and current assessment. Because of the one-year period of the double-blind,
participants who received the sham surgery initially did not receive the fetal tissue
surgery until more than a year after the baseline assessment. Thus, it was decided to use
the 12-months assessment as the new baseline for those who first received the sham
surgery and then the transplant. Likewise, scores for the 12 and 24-month assessment
used in this study were those following the actual fetal transplant.
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Preliminary Analyses
This section of the chapter is organized in the following manner: a) participant
response to questionnaires and interview; b) missing data; c) participants’ demographic
information; d) descriptive statistics related to the variables included in the study; e)
comparison of current participants to the rest of the cohort from the parent study; f)
reliability of variables.
Participant Response to Questionnaires and Qualitative Interview
Participants in the 2008 follow-up study were contacted via phone to assess their
willingness to participate in the current study, which consisted of an interview and
questionnaire. There were a total of five interviews completed; however, only four
completed questionnaires were returned.
The questionnaires measured several domains of QoL and Optimism that had
been assessed at previous time periods. Aspects of Physical functioning, Emotional
functioning, and Social functioning as well as Optimism were included in the
questionnaire.
The Physical functioning dimension of QoL was assessed using the patient
version of the Unified Parkinson’s Disease Rating Scale (UPDRS), including the
Activity of Daily Living, Severity of Symptoms, and the Free or Restricted scales. It
was intended that Physical Functioning would be analyzed as a composite variable,
which is consistent with previous analyses. However, the scales for Physical
Functioning were analyzed independently. The Emotional functioning dimension of
QoL was assessed by using the Center for Epidemiological Studies- Depression Scale
(CESD), the Intrusiveness of Illness Scale, and the Parkinson’s Disease Stress Scale.
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The State-Trait Anxiety (STAI-State) was not included in the current questionnaire. As
a result, the scales for Emotional Functioning (Center for Epidemiological StudiesDepression Scale (CESD), the Intrusiveness of Illness Scale, and the Parkinson’s
Disease Stress Scale) were analyzed independently. Social functioning (Social
Provisions Scale) and Optimism (Life Orientation Test Scale) were also analyzed
independently. The four questionnaires that were received in the current study were then
examined in contrast to data collected previously at different time periods, including
baseline (prior to surgery), 12 and 24-months after the transplant surgery and the10-12
year follow-up assessment conducted in 2008.
Missing Data
There were very little missing data in the questionnaires; however, there was one
questionnaire that was missing the Parkinson’s Disease Stress Scale. Most likely, the
participant simply skipped the page accidentally. With the exception of the one
questionnaire missing the Parkinson’s Disease Stress Scale, there were no other missing
data on the questionnaires.
Demographic Information
In the current questionnaire, there were several demographic questions
(Appendix J) that were used to collect information on the participants’ present status.
Information from the baseline questionnaire was also examined. The data is presented in
Table 1. While the majority of the participants do not currently work (four out of five),
three of the participants who completed the questionnaire are volunteering despite being
diagnosed with PD approximately 25-35 years ago (Table 1). Overall, the study was
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based on participants with PD who received fetal tissue transplantation surgery
approximately 13-15 years ago.
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Table 1
Demographic Information of Participants in the Current Investigation
Demographic
Information

Demographic Variables

Gender:
Male
0
Female
5
Age (from baseline assessment)
Mean years
46.00 ± 6.98
Range
40-56
Duration of disease
Mean years
28.20 ± 4.49
Range
25-35
Ethnicity - number
0
Native American
0
African American
5
Caucasian
0
Hispanic
0
Asian
Other
0
Duration of education completed (from baseline assessment)
Mean years
16.8 ± 2.75
Range
13 - 19
Current living situation - number (from current assessment)
Living with family
3
Living with friend or roommate
0
Living alone
1
Living in residential setting
1
Marital Status - number (from current assessment)
Never been married
0
Married or living with partner
3
Separated or divorced
0
Widowed
2
Currently paid for employment (from current assessment)
No
4
Part-time
1
Full-time
0
Volunteer work (from current assessment)
No
2
Yes
3
I used to, but no longer do
0
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Descriptive Statistics
In the current study, the descriptive analyses of the QoL measures were
performed (see Table 2). The descriptive analyses consist of the number of respondents
at each time period along with the means and standard deviations of each measure. For
each QoL dimension in the current study, there are five time periods representing
baseline (adjusted to reflect the assessment period immediately prior to surgery), 12
months after the transplant surgery, 24-months after the transplant, 10-12 year follow-up
conducted in 2008 and the current assessment.
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Table 2
Descriptive Statistics of QoL Variables for Baseline, 12-Months, 24-Months, 10-12 year
follow-up assessment in 2008 and Current Assessment
QoL Variable (includes time of assessment)
Physical Functioning
Activities of Daily Living at Worst Scale
Baseline
12 Months
24 Months
2008
Current
Severity of Symptoms at Worst Scale
Baseline
12 Months
24 Months
2008
Current
Free or Restricted Scale
Baseline
12 Months
24 Months
2008
Current
Emotional Functioning
Center for Epidemiological Studies –
Depression Scale
Baseline
12 Months
24 Months
2008
Current
Intrusiveness of Illness Scale
Baseline
12 Months
24 Months
2008
Current
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N

Mean

S.D.

5
5
3
4
4

32.00
26.20
16.30
25.25
30.50

3.67
9.20
2.08
6.29
5.26

5
5
3
4
4

14.60
13.00
9.70
13.00
17.50

2.51
4.36
2.31
2.00
0.58

5
5
4
4
4

4.40
3.20
2.00
2.63
4.25

1.34
1.64
0.82
0.48
1.71

5
5
4
4
4

7.40
8.00
6.25
9.50
16.25

4.98
6.21
5.91
5.45
7.80

5
5
3
4
4

59.40
64.00
50.00
61.25
74.25

23.80
22.76
17.78
22.85
17.50

Table 2
Descriptive Statistics of QoL Variables for Baseline, 12-Months, 24-Months, 10-12 year
follow-up assessment in 2008 and Current Assessment
Parkinson’s Disease Stress Scale
Baseline
12 Month
24 Month
2008
Current
Social Functioning
Social Provisions Scale
Baseline
12 Months
24 Months
2008
Current
Optimism
Baseline
12 Months
24 Months
2008
Current
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5
5
3
4
3

6.4
8.4
4
5.63
7.67

2.7
4.22
3.61
3.95
5.03

5
5
4
4
4

83.4
80.8
86
79.25
75.5

8.71
6.5
12.49
11.59
6.81

5
5
4
4
4

21.8
22.6
23
22
21.75

6.61
4.1
3.92
4.55
1.71

Differences Between Current Participants and Rest of Cohort in Parent Study
McRae et al. (2014) investigated the differences between the participants in the
current 13-15 year follow-up and the rest of the cohort that participated in the parent
study at baseline and 12 months. The results of the study are included in Table 3. Of
note, the baseline and 12 month assessment data was not shifted in the investigation by
McRae et al. (2014). The results of the investigation found that four participants reported
worse scores on the Activities of Daily Living Scale and Severity of Symptoms Scale at
baseline compared with the other 26 participants (McRae et al., 2014). Scores of
measures including Optimism, Perceived Social Support, Depression, Intrusiveness of
Illness and Stress improved over the 12 months for the four participants in the current
study and declined for the other 26 participants (McRae et al., 2014).
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Table 3
Differences between the Four Participants in the Current Study that Completed the
Questionnaire and the Rest of the Cohort from the Original Parent Study at Baseline and
12 months.

Demographics
Age
Gender
Duration

N=4
Mean (SD)
46.8 (6.3)
F=4
11.4 (4.0)

N=36
Mean (SD)
58.3 (9.7)*
F=15, M-20
14.1 (5.7)

Quality of Life

N=4

N=26

ADL's @ Worst 0
ADL's @ Worst 12

33.6 (2.1)
29.8 (5.6)

28.4 (6.8) ***
26.3 (6.6)

Severity @ Worst 0
Severity @ Worst 12

15.6 (3.4)
14 (3.7)

13.5 (2.3) *
12.5 (3.2)

Depression 0
Depression 12

38 (10.9)
26.2 (5.3)

31.9 (8.7)
33.7 (8.6) *

Intrusiveness 0
Intrusiveness 12

73.8 (21.9)
52.4 (20.6)

64.6 (16.3)
67.0 (13.8)*

7.4 (3.0)
6.4 (4.2)

6.1 (3.6)
7.2 (3.4)

Perceived Support 0
Perceived Support 12

80.4 (10.7)
88.6 (2.1)

80.3 (9.0)
77.7 (10.4)****

Optimism 0
Optimism 12

20.2 (5.9)
23.4 (4.6)

22.5 (5.5)
19.9 (3.9)*

Stress 0
Stress 12

* ≤ 0.10
** ≤ 0.05

*** ≤ 0.01
**** ≤ 0.001
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Reliability of Measures
Because of the small sample size in the current study, estimates of reliability
(Cronbach’s alpha) of all measures were obtained from the previous follow-up analysis
conducted at 10-12 year follow-up assessment (see Table 4; Cole, 2009). The Free or
Restricted variable of the UPDRS is a single item and no reliability coefficient was
calculated.
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Table 4
Reliability of QoL Measures for Current Assessment
QoL Measure at Current Assessment

Cronbach’s Alpha

Physical Functioning
Activities of Daily Living at Worst Scale
Severity of Symptoms at Worst Scale
Emotional Functioning
Center for Epidemiological Studies - Depression Scale
Intrusiveness of Illness Scale
Parkinson’s Disease Stress Scale
Social Functioning
Social Provisions Scale

.88
.68
.84
.94
.67
.95
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Primary Analyses
The previous section outlined the demographic information as well as other
preliminary analyses. The current section focuses on the analyses and results for the
research questions of the study.
Research Question #1
What is the trajectory of change in QoL for all the participants in the current study from
the baseline, 12 and 24 months after transplant, 10-12 follow-up assessment conducted
in 2008 and current 13-15 year follow-up assessment?
After examining the data, it was evident that with such a small sample size and
some missing data over the five time periods, using statistical analyses was not the most
effective way to approach the data. Instead, the means and standard deviation for each
variable at each time point were calculated and the means were plotted in order to
illustrate changes in the means across the five time points.
The profile plot presented in Figure 1, which shows the means of Activities of
Daily Living at Worst Scale at baseline, 12, and 24 months after the transplant surgery,
10-12 year follow-up assessment conducted in 2008 and current assessment (13-15 years
after the real surgery). There was an improvement in Physical functioning between
baseline assessment and 24-month assessment and then a decline in Physical
Functioning following the 24-month assessment.
Figure 2 demonstrates the line of progression of Activities of Daily Living at
Worst Scale for each participant at baseline, 12 and 24 months after the transplant
surgery, 2008 assessment and current assessment. Activities of Daily Living at Worst
Scale scores showed that the majority of the participants showed improvements in
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Physical functioning between baseline and the 24-month assessment and then a decline
following the 24-month assessment.
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Figure 1
Trajectory of Change in Activities of Daily Living at Worst Scale for Baseline to the
Current Assessment. (lower scores mean improved functioning)
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Figure 2
Changes in Activities of Daily Living at Worst Scale over time for Five Participants.
(lower scores means improved functioning)
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To examine changes on another aspect of Physical functioning, the means for the
Severity of Symptoms at Worst Scale are shown in the profile plot presented in Figure 3,
which shows the mean values of the Severity of Symptoms Scale at baseline, 12 and 24
months after transplant, 10-12 follow-up assessment conducted in 2008 and current 1315 year follow-up assessment. The means for the Severity of Symptoms Scale showed
improvements between baseline and the 24-month assessment and then a decline
following the 24-month assessment.
Figure 4 demonstrates the line of progression of the Severity of Symptoms at
Worst Scale for each participant at baseline, 12 and 24 months after transplant, 10-12
follow-up assessment conducted in 2008 and current 13-15 year follow-up assessment.
Three participants showed an improvement in Physical functioning between baseline and
the 12-month assessment; however, there was one participant that showed no change in
Physical Functioning and one participant that showed a decline in Physical Functioning
between baseline and the 12-month assessment. The majority of participants showed a
decline in Physical Functioning between the 24-month assessment and the current
assessment.
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Figure 3
Trajectory of Change in Severity of Symptoms at Worst Scale for Baseline to the
Current Assessment. (lower scores mean improved functioning)
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Figure 4
Changes in Severity of Symptoms at Worst Scale over time for Five Participants.
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To examine changes on another aspect of Physical functioning, the means for the
Free or Restricted Scale are shown in the profile plot presented in Figure 5, which shows
the mean values of the Free or Restricted for baseline, 12 and 24 months after transplant,
10-12 follow-up assessment conducted in 2008 and current 13-15 year follow-up
assessment. The means for the Free or Restricted Scale showed an improvement in
Physical Functioning between baseline and the 24-month assessment and then a decline
between the 24-month assessment and current assessment.
Figure 6 demonstrates the line of progression of the Free or Restricted Scale for
each participant for baseline, 12 and 24 months after transplant, 10-12 follow-up
assessment conducted in 2008 and current 13-15 year follow-up assessment. Most of the
participants showed an improvement or no change between the baseline assessment and
12-month assessment; however, there was one participant that was an outlier and showed
worse Physical functioning. The majority of the participants showed a decline in
physical functioning between the 24-month and current assessment. However, there was
one outlier (i.e., participant 2) who self-reported an improvement in physical functioning
between the 10-12 year follow-up assessment in 2008 and the current assessment.
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Figure 5
Trajectory of Change in Free or Restricted Scale for Baseline to the Current Assessment.
(lower scores mean improved functioning)
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Figure 6
Changes in Restricted or Free Scale over time for Five Participants.
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To examine the changes in Emotional functioning over the last 13-15 years, the
means and standard deviations were computed for each time period to examine changes
on three scales used to assess aspects of Emotional functioning includes the CESD, the
Intrusiveness of Illness Scale, and the Parkinson’s Disease Stress Scale across the five
time points (baseline, 12 and 24 months after the transplant surgery, 2008 and current
assessment).
A profile plot is presented in Figure 7, which shows the mean values for all
participants on CESD at baseline, 12 and 24 months after transplant, 2008, and current
assessment. There was a mild increase in depressive symptomology from baseline to 12
months and then decline in depressive symptomology between the 12-month assessment
and the 24-month assessment. From the 24-month assessment to the current assessment,
there was an increase in depressive symptomology.
Figure 8 demonstrates the line of progression of depression for each participant
for the baseline, 12 and 24 months after transplant, 2008, and current 13-15 year followup assessment. Across the first three time points, there were mixed results amongst the
participants with some participants experiencing an increase in depressive
symptomology and some participants experiencing a decrease. For three of the four
participants, there was an increase in depressive symptomology between the 2008 and
current assessment; however, there was a decrease in depressive symptomology for one
participant.

67

Figure 7
Trajectory of Change in CESD for Baseline to the Current Assessment. (lower scores
mean fewer depressive symptoms)
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Figure 8
Changes in CESD over time for Five Participants.
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To examine changes on another aspect of Emotional functioning, the means for
the Intrusiveness of Illness Scale are shown in the profile plot presented in Figure 9,
which shows the mean values of the Intrusiveness of Illness at baseline, 12 and 24
months after transplant, 10-12 follow-up assessment conducted in 2008 and current 1315 year follow-up assessment. There was an increase in the Intrusiveness of Illness
Scale between baseline and 12-month assessment as well as the 24-month assessment
and current assessment. There was a decline in the Intrusiveness of Illness Scale
between the 12-month assessment and 24-month assessment.
Figure 10 demonstrates the line of progression of the Intrusiveness of Illness
Scale for each participant for the baseline, 12 and 24 months after transplant, 10-12
follow-up assessment conducted in 2008 and current 13-15 year follow-up assessment.
Intrusiveness of Illness Scale increased in the majority of the participants between
baseline and the 24-month assessment. The Intrusiveness of Illness Scale increased
following the 24-month assessment in the majority of the participants.
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Figure 9
Trajectory of Change in the Intrusiveness of Illness Scale for Baseline to the Current
Assessment. (lower scores mean less intrusiveness)
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Figure 10
Changes in the Intrusiveness of Illness Scale over time for Five Participants.
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To examine change on another aspect in Emotional functioning, the means were
computed for the Parkinson’s Disease Stress Scale for each time period. A profile plot is
presented in Figure 11, which shows the mean values of the Parkinson’s Disease Stress
Scale at baseline, 12 and 24 months after transplant, 10-12 follow-up assessment
conducted in 2008 and current 13-15 year follow-up assessment. There was an increase
between baseline and 12-month assessment and then a decline between 12-month and
24-month assessment. There was an increase in stress between the 24-month assessment
and the current assessment.
Figure 12 demonstrates the line of progression of the Parkinson’s Disease Stress
Scale for each participant at baseline, 12 and 24 months after transplant, 10-12 follow-up
assessment conducted in 2008 and current 13-15 year follow-up assessment. The
Parkinson’s Disease Stress Scale increased for three participants and decreased for one
participants between baseline and the 12-month assessment. There was a decrease in the
Parkinson’s Disease Stress Scale between the 12-month and 24-month assessment for
the majority of the participants. There was an increase in Parkinson’s Disease Stress
Scale between 24-month assessment and the current assessment for two participants.
Overall, there were mixed findings on this scale for the participants over the last 13-15
years.
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Figure 11
Trajectory of Change in the Parkinson’s Disease Stress Scale for Baseline to the Current
Assessment. (lower scores mean less stress)
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Figure 12
Changes in the Parkinson’s Disease Stress Scale over time for Five Participants.

14

10

8

6

4

2

Participant 1

Participant 2

Participant 4

Participant 5

75

2013

2008

24 Months

12 Months

0
Baseline

Parkinson's Disease Stress Scale Mean

12

Participant 3

To examine the changes in the perceived social support over time, the means
were computed for the Social Provisions Scale for each time period. A profile plot
presented in Figure 13 shows the mean values of the Social Provisions Scale at baseline,
12 and 24 months after transplant, 10-12 follow-up assessment conducted in 2008 and
current assessment. There was a decline in perceived social support between baseline
and 12-month assessment, an increase between 12-month assessment and 24-month
assessment and then decrease between 24-month assessment and the current assessment.
Figure 14 demonstrates the line of progression of Social Provisions Scale for
each participant at baseline, 12 and 24 months after transplant, 10-12 follow-up
assessment conducted in 2008 and current assessment. There was a decrease in Social
Functioning for three participants between baseline and the 12-month assessment.
Social Functioning remained relatively stable between the 12-month assessment and the
current assessment with the exception of a decline in Social functioning for two
participants between the 10-12 year follow-up assessment and the current assessment.
Higher scores on the Social Provisions Scale indicate more perceived social support.
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Figure 13
Trajectory of Change in the Social Provisions Scale for Baseline to the Current
Assessment. (lower scores mean less perceived social support)
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Figure 14
Changes in the Social Provisions Scale over time for Five Participants.
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To examine changes in the Life Orientation Test (Optimism), the means were
computed for the Life Orientation Test for each time period. A profile plot presented in
Figure 15 shows the mean values of the Life Orientation Test Scale at baseline, 12 and
24 months after transplant, 10-12 follow-up assessment conducted in 2008 and current
13-15 year follow-up assessment. There was an increase in Optimism between baseline
and the 12-month assessment. Then there was a decline between the 12-month
assessment and 24-month assessment. There was an increase between the 24-assessment
and the 2008 assessment. There was a decline between the 2008 assessment and the
current assessment. Scores range from 0-32 with higher scores indicative of more
optimism (Scheier & Carver, 1985). The scale has a mean score of 21 (Scheier &
Carver, 1985).
Figure 16 demonstrates the line of progression of the Life Orientation Test Scale
for each participant at baseline, 12 and 24 months after transplant, 10-12 follow-up
assessment conducted in 2008 and current 13-15 year follow-up assessment. There was
no consistent pattern of change between baseline, 12-month assessment and 24-month
assessment. Optimism stayed relatively stable between the 24-month assessment and
current assessment. However, there was a decline in Optimism for one participant
between the 2008 assessment and the current assessment.
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Figure 15
Trajectory of Change in the Life Orientation Test Scale (Optimism) for Baseline to the
Current Assessment. (lower scores mean less Optimism)
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Figure 16
Changes in the Life Orientation Test Scale (Optimism) over time for Five Participants.
(lower scores mean less Optimism)
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Research Question #2 and #3
What are the individual experiences of the participants who participated in the doubleblind sham controlled transplantation study and original QoL study? Would the
participants, who participated in original transplantation study, volunteer to participate in
a future double-blind sham-controlled surgical trial?
To examine the personal experiences of the participants and to explore if they
would participant in a future surgery trial, participants were interviewed and recorded.
Transcripts of the recordings were made by the investigator and narratives based on the
interviews were developed for each participant. Individual stories for each participant
were developed. Each story was created by combining the individual responses to the
qualitative questions. Pseudonyms were given to each participant for confidentiality.
Narrative for Susan (pseudonym)
When asked to reflect on her experiences in the surgery trial in the beginning of
the discussion, Susan explained that she has had Parkinson’s disease for 40 years now
and she was diagnosed at the age of 35. She stated that “for [her], [the surgery] was
extremely successful” and she feels “very positive” about the experience. She explained
that she “was violently dyskinetic before the surgery so afterwards [she] got great
relief.” She then added that she stills gets dyskinetic but “not nearly to the extent that
[she] had been earlier.” She then explained important activities she has been able to do
in the years following the surgery, including developing a workshop for police officers
following an incident where she was almost arrested due to individuals in a mall
perceiving her as intoxicated or high on drugs. She explained how she and her husband
enjoy educating others about PD, and that it is a great passion for them.
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When asked how her feelings have changed over the years, she mentioned that
“she felt she didn’t have any other avenue “ for treatment at the time, and she was really
“down” after she got the first surgery because she wasn’t doing well. At that time, she
prayed that she didn’t get the real surgery because she wasn’t doing well. She reported
she did receive the placebo surgery initially and she had some “placebo benefits but
nothing [she] could dig [her] teeth in.” She reported, “That is one thing the transplant
did is restore some regulatory ability to my body” and she expressed that “even if you
can stop where you are, that is a huge improvement with a chronic illness.” She then
explained how the surgery gave her “a second chance” in life. She noted that she was
able to sleep more than two hours per night, eat and gain weight, talk on the phone
without dropping it or flinging it around the room, and walk to the end of the driveway
and back. She acknowledged that she was not able to do these activities previously. She
discussed how being able to “make [friends] a cup of tea” was a big improvement. She
stated she overall felt as though “life was starting over again” after the transplant
surgery.
After discussing her experiences, she was asked if she would participate in a
similar surgery trial in the future and she stated, “[She] absolutely would! I learned a
lot.” She went on to say that “the major problems were cured and new problems arose
that come with a chronic illness.” She then described the surgery as “some new defense
that you didn’t have before.” Her husband expressed more fear regarding the process
and indicated how it was a dangerous process because once the cells are implanted, there
is no control over them. He also noted he worried regarding his wife experiencing
adverse effects. With that said, he stated he would agree that he would recommend she
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do a similar surgery trial in the future given that it would be intended to combat the
illness, which is always beneficial.
Susan was then asked what were the positives of participating in the surgery trial
and she stated the “outcome” and “knowing there was an opportunity to get better.” But
when asked the negative aspects of participating in the surgery trials, she noted the
negative was “not knowing [if it would be beneficial].”
While discussing what advice would she give to future participants of a surgery
trial, she stated to “make sure you understand the risks” associated with the study and
then “don’t be afraid to speak up.” She explained further that there is “nothing that is
too little to be dealt with.” She explained that when people enter into a surgery trial,
they need to “trust [the researchers].” Her husband stated that one should understand
what the doctors want before you enter into the surgery trial. He also explained how
important it is to accept that things may go wrong during the surgery trial and he
emphasized the importance of preparing the other people in your life regarding why the
participant is participating in the study and what the outcome may be at the end.
At the end of the interview, Susan stated she never got to speak with other
participants and how it would have been helpful to speak with them following the trial.
Narrative for Nancy (pseudonym)
The interview began with a discussion regarding reflecting back on her
experiences in the surgery trial and she quickly stated that she felt the surgery was “a
work in progress” and explained that the surgery didn’t improve her symptoms of PD
past the first month. Whether or not she had the real or sham surgery was discussed and
she indicated she had the sham surgery first. She acknowledged benefits from the sham
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surgery for one month including improvements in her balance and her overall tightness.
She explained that her benefits following the real surgery were no better than with the
sham surgery.
The discussion then went on to explore the negatives of the surgery trial and she
stated she felt as though the physicians were “done with [the participants]” at the end.
She indicated that it was a real sacrifice to participate in the study, especially with three
young children. As soon as her children entered the conversation, her mood shifted a bit
and she became positive as she expressed great pride in how her children turned out.
She then explained she was diagnosed at age 26 and she had the surgery when
she was 38 years old. She indicated that she has been able to keep going as a result of
having deep brain stimulators (DBS) inserted in 2005 or 2006. She reported that she has
found DBS helpful in addressing her worst symptom, which she stated is walking. She
stated DBS has “given [her] a whole new start.”
She was asked if her feelings regarding her participation in the surgery trial have
changed over the last 13-15 years and she stated “not really.” She explained that it was a
trial and explained how it is important to remember that. She acknowledged that she
was glad she went through the trial since there was an opportunity to have input if it
worked. She was then asked if she would do it again. She explained that she is older
now and doesn’t know if it would be worth it.
While discussing if there were any positive aspects of participating in the study,
she noted she enjoyed “seeing other people at the level they were at.” In other words,
she found it helpful to see others with the disease but at different stages of the disease.
There was then an inquiry regarding the worst aspects and she stated it was the time
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when she was waiting to find out why it didn’t work for her and the overall results of the
study.
The discussion ended up with a reflection on regarding what advice she would
give to future participants, and she said, “Go and have it done. If it helps, you are lucky.
If it doesn’t help, maybe there is something else down the road.”
Narrative for Piper (pseudonym)
In looking back on her experiences in the surgery trial, Piper stated that she
believes it is something she would do again overall and that she has no regrets. In the
surgery trial, she acknowledged that she had the sham surgery initially and then
underwent the real surgery.
Towards the end of the surgery trial, however, she felt “abandoned” and went on
to explain that everything was moving so quickly and then all of a sudden, there was
nothing. While she was grateful for the care of the nurses and physicians, at the end of
the study, she felt as though “all of sudden [the participants] were nothing.”
She went on to explain how it would have been helpful to have support towards
the end of the trial due to her experiencing ups and downs in regards to her symptoms.
She stated it would have been helpful to know what was expected and if her symptoms
were normal. She pointed out that there was no one to guide her towards the end of the
trial and give her any information. She stated she could feel the medical staff “losing
interest.” She expressed sadness and stated, the participants “put time and energy into it,
too.”
Regarding whether she would be willing to go through a similar surgical trial for
a second time, she stated yes and explained that she felt like she was a small part of
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future technology that would one day find a cure. In regard to personal benefits to her
own health, she stated “I don’t know what I would be like if I didn’t have it.” She also
stated she had DBS surgery approximately 8 years ago as well. She explained that it is
hard to tell the benefits for her since her dyskinesias are different; she experiences both
dyskinesia and dystonia at the same and experiences more of a rolling than a jerking
movement.
Over the last 13-15 years, she stated her feelings regarding participating in the
trial have not changed and she has always been glad she participated in the trial stating,
“I wanted to be on the cutting edge.” She explained further that she is a “risk taker,”
which she attributed to being a single parent and taking on new endeavors in her work
life. She explained that the experiences she had in the trial were unique and she would
have never had those opportunities without the trial.
The discussion then turned to the waiting period between the sham surgery and
the real surgery, which lasted approximately one year for her. She stated it was
“difficult” to wait that long. She explained that every Monday she thought the phone
call would come telling her she could undergo the transplant surgery. However, she
stated that instead of receiving a call from them, she had to follow-up with the doctors,
only to find out that she need to wait several more months. She explained that time as
“living week to week.”
She went on to recall the weeks following the sham surgery and how she was
convinced she had the real surgery initially due to “feeling better.” She stated that when
she found out she got the sham surgery, she “kept on because [she] felt [she] was
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representing people with Parkinson’s.” She went on to say, “I had to stay positive even
though deep down, I didn’t believe it.”
During the last part of the interview, she was asked what advice she would give
to future participants who would participate in a surgery trial. She stated “ you can’t do
it if you don’t believe in it. You have to really believe in it. You have to be positive
about it.” She went on to say that, “a lot of Parkinson’s has to do with your attitude” and
stated that if you don’t make the most out of your situation, “you only hurt yourself.”
Narrative for Melissa (pseudonym)
The interview began with her feelings regarding her experiences in participating
in the fetal tissue surgery trial. She noted that at the beginning, she was “full of hope.”
At that time, she was “hopeful that it would be a cure but it wasn’t.” She went on to
explain her symptoms three years post-surgery and stated she did pretty well. She was
walking and she felt “in control of [herself].” Furthermore, she stated she was “full of
pep” and her “tremors weren’t too bad.” However, she acknowledged wearing off
effects around three years. More specifically, she noticed her left side was getting
affected and up until that point, her left side was not affected by her PD. She stated at
this time, she realized that the “Parkinson’s wasn’t wearing off, [she] was wearing off.”
The conversation then explored her feelings in the beginning of the surgery trial.
She stated that in the beginning, “[she] felt very special.” She explained that she and her
husband were recently married at the start of the study and stated they worked hard to
join the study. She acknowledged that during the period following surgery, there were
several follow-up appointments where she explained how she felt “very challenged and
[she] wanted to do well.” She then found out that she had the real surgery; however, she
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found out the fetal tissue cells in one part of her brain “didn’t take.” She also stated that
she had some medical complications including hypertension and it was unclear at that
time if her health issues were related to having the fetal tissue cells implanted. She
explained that she had to be taken off of her PD medications, which caused her
functioning to decline and explained that as a result, the effects of the surgery didn’t last
long. When the effects of the surgery wore off, she explained that she experienced mild
depression and began searching feverishly for new treatments. At that time, she felt as
though she was “back to square one.”
She was then asked how her feelings of participating in the surgery trial have
changed over time. She acknowledged that at the beginning, she was filled with hope
and she felt as thought she was “dedicating [herself] to science.” She then stated she
does not regret being a volunteer when she reflects back on her experiences. She also
stated that if there were any real prospects for improvements, she would participant in a
similar study again.
While inquiring regarding the most positive aspect of participating in the study
for her, she stated it was the attention she got during the study. When she was queried
further, she stated she was compared to other individuals and she was invested in doing
well. She stated she wanted the study “to be a success.” The discussion was then
directed to the negative aspects of participating in the study and she stated the most
negative aspect was having her symptoms return and then become worse.
Regarding advice for future participants, she stated individuals frequently come
to her for advice regarding PD and what medications they should take since she has had
PD for 28 years. For instance, she has a friend who resides near her who comes to her
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for advice and she told her that you have to tell the doctor what you feel and you need to
be honest with the medical providers. She also told her friend that if you are not ready to
take medications and if you feel you can cope without the medications, then tell the
medical providers you are not ready. She placed importance on being true to yourself
and standing up for yourself.
She then went on to explain that she enjoys pushing herself and explained that
she will push herself to walk outside when she is getting picked up by friends instead of
waiting inside. She expressed that pushing herself gives her a “sense of importance.”
At the end of the interview, the discussion turned to her support system during
the surgery trial and she explained that her husband was “ a terribly good sport.” She
explained that he was “about helping me” and she didn’t think she “could have done it
without his help.” She explained that when he died, she felt “abandoned,” but she has
good friends and she is now in a new romantic relationship.
The final question discussed was what she would tell someone else going
through a similar surgery trial. She stated she would “ask them if they have close friends
and family.” She then went on to say, “they would need people they care about being on
their side” and explained that they would need to have “a conviction about helping
others and science.”
Narrative for Jenny (pseudonym)
While reflecting back on her overall experience in the surgery trial, she stated she
feels “very positive” regarding her experience in the transplant surgery trial. She then
went on to say that she had “a very good result” from the transplant surgery trial and she
explained that she was able to resume her life as a practicing neurologist as a result of
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the transplant surgery. She then went on to discuss her medical history and she noted
she was diagnosed with PD around 1989. She stated she is currently experiencing
balance difficulties and she is unclear if her balance difficulties are related to her PD or
her history of scoliosis.
The discussion then turned to the next question regarding how her feelings have
changed about her participation in the surgery trial over time. She indicated she has
been “confident about it since the very beginning.” She went on to explain that she
knew she received the real transplant surgery initially because the doctors were
“spending more detail” than they would if they weren’t putting something in her brain.
She also noted she felt the needle pass the blood-brain barrier due to experiencing pain.
When asked if she would participate in the surgery trial again, she quickly said yes.
When asked to elaborate, she stated “there is nothing out there that could have given me
as good of results or any results at all.” She noted that she doesn’t believe the
neurostimulators are ideal for her type of Parkinson’s. She explained that the year
following the transplant surgery, she was off all her medications and she was able to
“feel like [herself].”
The next question explored the negative aspects of participating in the transplant
surgery trial. She initially stated, “I don’t know.” She then was probed to explore the
question further by exploring the attention she received since she was the patient that
experienced a brain hemorrhage as a result of the transplant surgery. She indicated the
attention she received was “bothersome.” The discussion then turned to when the study
ended and how some participants felt forgotten. She stated that was true for her as well.
She explained further that it was “sad the study did not go any place.”
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She was then asked what advice she would give to future participants who
participate in a fetal tissue surgery trial. One piece of advice was that if you decide to do
it, “act like a patient and do what you are told.”
Towards the end of the interview, the discussion turned to a more personal topic,
her experiences when she was first diagnosed. She stated her relationships have been
“formed and deformed by Parkinson’s.” She noted that her children had to cope with a
“mother who moved funny.” But she says she is grateful she is still working and she
was able to get married again. She also noted she was able to watch her children grow
up. She stated regarding friendships, “it is not generally up to me, it is up to those who
socialize with me.” She explained that people look differently at those with chronic
illness. She explained that she “never felt totally comfortable with my friends and
colleagues. They looked at [her] as a person with Parkinson’s’ not a person.” She then
went on to explain how she was recently introduced by a student at a symposium and the
student stated she was a fabulous teacher and she explained how wonderful it was for
someone to acknowledged her as a person and teacher, rather than to see her primarily as
someone with PD.
Summary
Chapter Four presented the results of the preliminary and primary analyses
associated with the current study. In the beginning of the chapter, the results of the
preliminary analyses were discussed, which was followed by the results of the primary
analyses.
To answer the first research question, the means of all the measures were
computed over five time points: baseline, 12 and 24 month following the transplant
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surgery, 10-12 follow-up assessment in 2008 and current assessment and then plotted to
determine changes in the means over the last 13-15 years. The means for each
participant were also computed and plotted to assess the changes from baseline through
the current assessment. In response to the second and third research questions, the
information gathered from the qualitative interviews was presented in narratives that
described the participants’ individual experiences in regard to the surgical trial.
Chapter Five discusses the results presented in Chapter Four as well as
connecting both the quantitative and qualitative data. Additionally, the limitations
associated with this study and recommendations for future research are discussed.
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Chapter Five
Discussion
Overview
Chapter Five presents the following topics: a) summary of the current study, b)
discussion of the overall findings from the primary analyses, c) connecting of the
qualitative and quantitative data) d) limitations of the study, e) recommendations for
future research, and f) conclusions.
Summary of the Study
Parkinson’s disease (PD) is a chronic illness that impacts every aspect of an
individual’s life including emotional, physical and social functioning. There have been
significant improvements in the treatments for PD including the introduction of surgical
treatments over the last few decades. In 2001, Freed et al. investigated the effects of
fetal tissue transplantation in participants with PD by conducting a double-blind shamcontrolled surgery trial. Results showed human embryonic dopamine-neuron transplants
survived in all patients and there were some clinical benefits in younger participants
(Freed et al., 2001). While the parent study was being conducted by Freed et al. (2001),
there was also a study that was conducted by McRae et al. (2004) that examined if QoL
improved in participants in the transplant group compared to the sham group after the 1year period of the double-blind was lifted in the study conducted by Freed et al. (2001).
However, there has been limited research examining the long-term impact of these
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surgical treatments on QoL in persons with PD. In addition, there is little known
regarding the long-term impact on QoL in the participants that participated in the
double-blind, sham controlled transplant surgery trial from a qualitative perspective.
In the present study, the longitudinal changes in QoL in the participants after
undergoing the fetal tissue transplantation surgery approximately 13-15 years ago were
examined from both a quantitative and qualitative perspective. There were a total of five
participants who participated in the parent study (Freed et al., 2001) and original QoL
study (McRae, 2004). All five participants completed the interview to gather qualitative
information regarding their personal experiences over the last 13-15 years and four
participants completed the questionnaire that measured several dimensions of QoL as
well as optimism. The information gathered in the current study was plotted along with
the data collected at baseline, 12 and 24 months after transplantation as well as the
previous 10-12 year follow-up conducted in 2008. The change over time in QoL was
then charted for each participant as well as average scores at each time point on each
measure. Interviews were transcribed and narratives were developed to present the data
gathered in the qualitative interview. In addition, the narratives of the participants’ were
coded for themes in order to describe the experiences of the participants in the unique
study. The following research questions were addressed in the current study:
1. What is the trajectory of change in QoL for all the participants in the current
study from the baseline, 12 and 24 months after transplant, 10-12 follow-up
assessment conducted in 2008 and current 13-15 year follow-up assessment?
Because of the small sample size, no statistical analyses were performed. Instead,
the averages for the participants on each measure were calculated and then
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plotted to examine the changes over time. In addition, individual scores on each
of the measures were plotted over time.
2. What are the individual experiences of the participants who participated in the
double-blind sham controlled transplantation study and original QoL study?
3. Would the participants, who participated in original transplantation study,
volunteer to participate in a future double-blind sham-controlled surgical trial?
Discussion of Overall Findings
In the current study, the first research question examined the trajectory of change
in QoL (Emotional, Social and Physical functioning) and Optimism over the last 13-15
years in the participants in the fetal tissue transplantation surgery trial conducted by
Freed et al. (2001). The average scores were first plotted on the three measures of
Physical functioning: Activity of Daily Living at Worst Scale, Severity of Symptoms at
Worst Scale and Free or Restricted Scale across the five time points including baseline,
12 and 24 months after the transplant surgery, 10-12 year follow-up assessment in 2008
and the current assessment. The results of the quantitative investigation showed that the
means for the Activity of Daily Living Scale showed improved Physical functioning
from baseline to the 24-month assessment and then a decline in Physical functioning
between the 24-month assessment and the current assessment. In addition, the
individual scores for each participant were plotted for the Activity of Daily Living Scale.
The individual scores on the Activity of Daily Living Scale revealed that the majority of
the participants demonstrated improvements between baseline and the 24-month
assessment. In addition, the majority of the participants showed worsening physical
functioning between the 24-month assessment and the current assessment.
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The mean scores on the Severity of Symptoms Scale showed a similar pattern to
the Activities of Daily Living Scale and there was an improvement in Physical
functioning from the baseline assessment to the 24-month assessment followed by a
decrease in Physical functioning between the 24-month assessment and the current
assessment. The individual scores revealed that there was one participant that selfreported worsening physical functioning at the 12-month assessment followed by an
improvement at the 10-12 year follow- up assessment in 2008. The majority of the
participants demonstrated improvements in functioning between baseline and the 24month assessment. All of the participants self-reported worsening functioning following
the 24-month assessment. The qualitative interviews revealed that while several
participants have undergone additional procedures (e.g., DBS), they continue to
experience a decline in their physical functioning.
The mean scores for the Free or Restricted Scale showed an improvement
between the baseline assessment and the 24-month assessment and decline in physical
functioning between the 24-month and the current assessment. The individual scores on
the Free or Restricted Scale showed that the majority of participants demonstrated an
improvement in physical functioning between the 12-month and 24-month assessment.
In addition, the majority of the participants showed a decline in how free or restricted
they felt between the 24-month and current assessment. However, there was one outlier
(i.e., participant 2) who self-reported an improvement in physical functioning between
the 10-12 year follow-up assessment in 2008 and the current assessment. The qualitative
data for participant 2 revealed that she had DBS surgery performed in 2005 or 2006,
which may explain the improvements in her physical functioning.
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The means of all the measures of Emotional Functioning (Center for
Epidemiological Studies-Depression (CESD) Scale, Parkinson’s Disease Stress Scale
and Intrusiveness of Illness) were then compared over the five time points as well as the
individual scores across all five time points. On the CESD, participants experienced a
slight decrease in depressive symptomology between the 12 and 24-month assessment
and then a gradual increase in depressive symptomology following the 24-month
assessment. On the CESD, possible scores range from 0-60 with higher scores being
more indicative of depressive symptomology (Radloff, 1977). The average score in the
current assessment on the CESD Scale was 16.25 for the current assessment. It is
important to note that higher scores do not indicate that an individual meets the clinical
criteria for depression. In other words, a higher score on the CESD is indicative of more
depressive symptoms. In reviewing the individual scores at the current assessment, two
participants obtained scores of 9 and 10 and the other two participants received a score
of 23. Overall, it is surprising that the level of depressive symptoms was not higher
across time given the progressive nature of their illness and declining physical health.
The average scores were analyzed for the Parkinson Disease Stress Scale across
the five time points, which revealed a gradual increase in stress from the 24-month
assessment to the current assessment. Notably, there was a decrease in stress between the
12- and 24-month assessments. It was interesting that the stress level was higher at 12months compared to the current assessment despite the increase following the 24-month
assessment. The individual scores showed that an increase in stress for three participants
at the 12-month assessment. In addition, the individual scores of the Parkinson Disease
Stress Scale revealed that two participants showed an increase in stress following the 2498

month assessment, while one participant showed a decrease in stress between the 10-12
year follow-up assessment and the current assessment. The qualitative data allowed for
insight into the high level of stress at the 12-month assessment. At the 12-month
assessment, many participants indicated they felt abandoned by the researchers, which
may explain the high level of stress.
The participants’ level of Intrusiveness of Illness was assessed and there was a
similar pattern with the other two measures of Emotional functioning. The level of
Intrusiveness of Illness decreased between the 12 and 24-month assessments and then
increased following the 24-month assessment. The individual scores on the
Intrusiveness of Illness scale revealed that the majority of participants reported an
increase in Intrusiveness of Illness between the 2008 and current assessment. Of note,
there was a decrease in Intrusiveness of Illness for three participants between the 12month and 24-month assessment. Overall, the measures of Emotional functioning
showed a worsening in Emotional functioning (e.g., depression, stress and intrusiveness
of illness) between 2008 and the current assessment. However, the degree to which their
Emotional functioning declined is less than expected given the progression of the
participants’ PD. Several participants noted in the qualitative interviews that they
continue to be active in their lives and contribute society in different ways such as
volunteering. These factors may explain why the decline is less than what would be
expected.
Social functioning was assessed using the Social Provision Scale and the average
score for each time period was plotted to determine changes over the last 13-15 years.
The results showed that at 24-months, the participants showed the highest degree of
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perceived support. Following the 24-month assessment, there was a decline in the level
of perceived support amongst the participants. Prior to the 24-month assessment, there
was a decline in perceived social support at the 12-month assessment. The individual
scores for the participants on the Social Provision Scale revealed a significant decline in
perceived social support between the baseline and 12-month assessment. There were two
participants who reported a decrease in perceived social support between the 10-12 year
follow-up assessment in 2008 and the current assessment. Two participants showed a
slight increase in social support.
The trajectory of change in Life Orientation Test Scale (Optimism) was
examined over the five time points: baseline, 12 and 24-month assessments, 10-12 year
follow-up conducted in 2008 and the current assessment. The average scores for each
time point were computed. There was an increase in Optimism between baseline and the
12-month assessment. Then there was a decline between the 12-month assessment and
24-month assessment. There was an increase between the 24-assessment and the 2008
assessment. There was a decline between the 2008 assessment and the current
assessment. A higher score is indicative of greater Optimism. Overall, the average scores
of Optimism are higher than might be expected given the circumstances. The individual
scores on the Life Orientation Test Scale over the five time points revealed that
Optimism fluctuated between the baseline assessment and 24-month assessment. There
were some participants who showed an increase in Optimism while others showed a
decrease. Between the 24-month assessment and the current assessment, Optimism has
remained relatively stable with the exception of one participant who exhibited a decline
in Optimism and one participant who exhibited a slight increase in Optimism.
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There is very limited research on the longitudinal impact on Quality of Life in
individuals with Parkinson’s over time. Thus, there is very little to compare the current
quantitative findings to in the literature. There was one study conducted by Lezcano et
al. (2004) that investigated the improvement in quality of life in individuals with
Parkinson’s disease after undergoing bilateral deep-brain stimulation in subthalamic
nucleus. The study found improvement in Quality of Life in 62 percent of the
participants following two years after surgery (Lezcano et al., 2004). However, the study
did not extend beyond two years and thus, it is difficult to compare the current findings
to the study conducted by Lezcano et al. (2004). More research needs to be conducted on
the long-term impact of undergoing a surgery trial on Quality of Life in individuals with
PD.
In addition, a separate analysis of the data, where the current four participants
who completed the questionnaire were compared to the rest of the cohort at baseline and
12 months, revealed that the participants in the current assessment showed
improvements on several measures over the 12 months (McRae et al. 2014). The rest of
the cohort; however, showed a decline on several measures including optimism,
perceived support, depression, intrusiveness and stress (McRae et al., 2014).
While the quantitative data demonstrated change in QoL over the five time
points, the quantitative results does not provide any context or possible explanations for
changes on the different dimensions of QoL. Qualitative interviews were conducted in
order to gain insight into the individual lives of the participants who participated in the
unique double-blind, sham controlled surgery trial. The responses of the participants
were then coded for themes and narratives were created to present the findings of the
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qualitative interviews. The qualitative data are rich with life experiences of these
individuals and give a unique look into their individual lives during the last 13-15 years.
The participants spoke candidly regarding the surgery trial and how their feelings have
changed over the years as well as some of the most negative and positive aspects of
participating in the surgery trial.
There were several themes that emerged during the qualitative interviews. The
first theme that emerged was the feeling of being “dropped” or “abandoned” following
the surgery trial. Several participants reported that while they received benefits from the
surgery trial, their experiences were not validated due to the overall results of the study
not being what was expected. Several participants also discussed the time and energy
they dedicated to the study and how it was disappointing to feel “abandoned” at the end.
For instance, one participant reported that she and her husband spent hours filming her
current functioning in order to be accepted into the study and then spent numerous hours
flying and traveling to the participate in the surgery trial. The feeling of being
“abandoned” may explain the high level of stress at the 12-month assessment, which was
essentially the end of the study for her.
A second theme that emerged from the data was the feeling of contributing to a
larger cause and feeling as though as their participation in the surgery trial was one step
closer to finding a cure for PD. The individuals in the current study expressed a strong
desire to participate in research and to help contribute to the body of knowledge on PD.
It was that desire that appeared to help participants be resilient when they experienced
difficulties during the trial. This was evident by the fact that many of them stated they
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would participant in the surgery trial for a second time and the majority of them felt
positive overall regarding their experiences in the surgery trial.
The third theme that emerged from the data was the fact that the participants in
the current study demonstrated a strong desire to live their lives to the fullest despite
coping with PD for a long time. One participant (current age is 74) stated that she
recently began dating again and she makes herself walk to the sidewalk when her friends
pull up in their car to pick her up. Several other participants continue to volunteer and
several indicated they participate in activities in order to educate others on PD.
Connecting of the Quantitative and Qualitative Data
The qualitative and quantitative data allows a unique insight into the lives of the
participants who participated in the fetal tissue surgery trial conducted by Freed et al.
(2001) approximately 13-15 years ago. The qualitative data can provide possible
alternative explanations for changes in QoL beyond the scope of the fetal tissue surgery
trial. For instance, many of the participants have experienced loss of loved ones,
changes in social support, changes in employment, additional procedures in order to
alleviate symptoms of PD, and changes in how they view the trial and their current
functioning.
In examining the level of depressive symptoms in the participants, it was
interesting that several participants self-reported a minimal level of symptoms despite
having a chronic and progressive illness and decline in physical functioning. The
qualitative interviews revealed that many of the participants continue to be active in
society and contribute to the world’s knowledge regarding PD. Despite many of the
participants not currently being employed, the majority of the participants are
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intrinsically motivated to be active and contribute to society. In future studies, including
individuals who are intrinsically motivated to contribute to society through their lives,
their work or volunteer activities would most likely help participants be resilient in the
face of adversity during surgery trials. These common factors amongst the group of
participants in the current assessment may also explain that minimal decline in other
scales such as the Intrusiveness of Illness Scale and Optimism Scale. These findings in
the interview are also consistent with the findings that the four participants in the current
assessment showed improvement on several measures between baseline and 12 months
compared to the rest of the cohort that participated in the parent study conducted by
Freed et al. (2001). These individuals appear to be functioning better than the rest of the
cohort on several emotional and social measures, which may serve as a protector factor
for them over a long period of time despite having a chronic and progressive illness.
Another interesting finding in the data gathered was the importance of social
support in coping with the surgery trial. Many participants stated they relied heavily on
their significant others or extended family members during the initial stages of the
surgery trial. In addition, at the current assessment, many of the participants continue to
have strong support despite a decrease since previous time points in the quantitative
data. Several participants have had significant others pass away since the start of the
surgery trial. However, many of them have gone on to find new partners or remarry. In
addition, it was evident in the interviews where the significant others were present that
they also had a desire to increase knowledge regarding PD and exhibited a large
investment in research. In future studies, it will be pertinent to not only assess the
participant’s ability to go through a surgery trial, but also assess their family members’
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willingness and ability to participate in the surgery trial. Furthermore, social support is
also crucial for the period of time following the surgery trial, where participants may feel
“abandoned.”
Overall, the participants in the current study are remarkable human beings who
have contributed significantly to our body of knowledge regarding PD and they are an
inspiration in their ability to overcome adversity and live very meaningful lives
especially after living so many years with a chronic and debilitating illness. The data
obtained in qualitative interviews gives the quantitative information a context and assists
in understanding the quantitative data more holistically.
Recommendations for Future Research
Recommendations for future research include establishing a comparison group.
As future surgery trials with participants with PD take place, it will be helpful to
compare the participants in the current assessment with participants who receive
“standard” treatment. The comparison will allow an investigation into similarities and
difference amongst those who received the transplant and another group of participants.
This research will assist in furthering our knowledge regarding why participants did well
in this surgery trial and why other participants did not do well. The findings in the
current surgery trial suggest that the motivation to contribute to research regarding PD
was helpful in coping with adversity and difficulties during the transplant surgery trial. It
would be interesting to examine if this was true in similar research trials with persons
with PD. In addition, perceived social support worsened at the 12-month assessment,
which may be related to the feeling of being abandoned. It would be interesting to
compare this to similar trials to see if perceived social support shifted at the end of the
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study. The investigation in our social support changes as the study comes to an end
might help researchers establish more effective ways of terminating surgery trials with
participants.
Another area for future research would be to assess changes in QoL from both a
quantitative and qualitative perspective with a larger sample, which would allow for the
quantitative data to be analyzed statistically to determine the changes in QoL are
statistically significant. However, this may be difficult given the limited amount of
research in this area.
Future research is this area is needed to further identify factors that help
participants do well in surgery trials in order to possibly adjust or focus the recruitment
of participants on those with certain characteristics. More in depth analysis of available
data at all the time points may allow for the specific identification of factors that exist
amongst the participants who did well in the overall study. Another area of future
research would be to examine all the transcripts from the different time points to further
assess changes in QoL amongst the participants. This would allow for further
examination into how their perspectives have changed over the last 13-15 years.
Furthermore, it would be interesting to compare the quantitative data using the original
baseline with the shifted baseline in order to gain an additional perspective.
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Conclusions
The objective in the current study was to examine changes in QoL over the last
13-15 years in participants who participated in the fetal tissue transplant surgery trial.
The current study is unique in regards to the longitudinal perspective from both a
quantitative and qualitative perspective with individuals who participated in a unique
surgery trial approximately 13-15 years ago.
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Appendix A
Letter Sent to Participants with Questionnaire
Dear [name],
Thank you so much for participating in the 13-15 year follow-up to the original
fetal tissue implant study for the treatment of Parkinson’s Disease. It was such a pleasure
to meet you during the phone interview. I have enjoyed learning about your experiences
of participating in the double-blind, placebo surgery trial and the impact your
participation has had on all the different aspects of your life as well as lives of your
family members.
During the phone interview, Cyndy McRae and I discussed the questionnaire that would
be sent in the mail. I apologize for the delay in getting the questionnaire to you. I
recently got married and moved to a different state to start my pre-doctoral internship. I
have enclosed the questionnaire for you to complete. The questionnaire is to help us
gather additional information about you and your participation in the fetal implant
surgery trial. Please complete all the questions on the questionnaire. Please return the
questionnaire in the postage paid envelope.
Thank you so much for your time and willingness to share your experiences with Cyndy
and I. Your contributions are incredibly beneficial to our knowledge regarding
Parkinson’s Disease and the treatments of Parkinson’s Disease.
Please feel to email Cyndy McRae at Cynthia.McRae@du.edu or Jessica Kuhne at
jessicakuhne@hotmail.com if you have any questions or concerns.
Again, thank you so much for your time. I have really enjoyed speaking with you and I
look forward to receiving your completed questionnaires.

Sincerely,
Jessica Kuhne
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Appendix B
Unified Parkinson’s Disease Rating Scale (UPDRS) – Patient Version
How well can you perform these daily activities AT YOUR WORST?
(check one for each row)

Normal

Adequate

Limited

Need Help

Unable To Do

Walking

____

____

____

____

____

Dressing

____

____

____

____

____

Cutting food

____

____

____

____

____

Hygiene

____

____

____

____

____

Getting up from chair

____

____

____

____

____

Turning in bed

____

____

____

____

____

Writing

____

____

____

____

____

Talking

____

____

____

____

____
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Appendix C
Severity of Symptoms
Please rate the severity of each of the following problems AT YOUR WORST.
(check one for each row)

Normal

Mild

Moderate

Severe

Very Severe

Tremor

____

____

____

____

____

Swallowing

____

____

____

____

____

Salivation

____

____

____

____

____

Freezing when walking

____

____

____

____

____

Falling

____

____

____

____

____
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Appendix D
Free or Restricted Scale

Overall, how free or restricted do you feel in doing what you want to do?
(check or circle the appropriate number)

1

2

3

4

I still do everything
I want to do

5

6

7
I can no longer do the
things I want to do
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Appendix E
Parkinson’s Disease Stress Scale
Below you will find a list of stressful situations that may occur because of your physical
symptoms. Please check “Yes” or “No” to indicate whether or not an item causes you
considerable stress, or clearly bothers you.
Yes

No

____

____

1. Sometimes I am embarrassed in public because of my symptoms.

____

____

2. I attract attention in public because of my symptoms.

____

____

3. Friends and acquaintances do not take my symptoms seriously.

____

____

4. I cannot make new friends because of my disease.

____

____

5. I am anxious about the uncertainty of the future of my disease.

____

____

6. I worry a great deal about my symptoms.

____

____

7. I worry so much about my disease that all other things become
unimportant.

____

____

8. My physical condition tends to determine all that I think and do.

____

____

9. I feel like a disabled person.

____

____

10. I feel a sense of helplessness and anger because I cannot influence
my disease.

____

____

11. The lives of my loved ones have changed because of my disease.

____

____

12. Even members of my family cannot really understand the
difficulties I face.

____

____

13. My partner and my family take too little notice of my disease.

____

____

14. I am concerned that my family members restrict themselves too
much because of my disease.

____

____

15. Sometimes I think my partner may leave me because of my
disease.
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Appendix E, continued
Parkinson’s Disease Stress Scale
Below you will find a list of stressful situations that may occur because of your physical
symptoms. Please check “Yes” or “No” to indicate whether or not an item causes you
considerable stress, or clearly bothers you.
Yes

No

____

____

16. Because of my disease I have had to give many personal
responsibilities over to my partner or family members.

____

____

17. Because of my disease I have had to give up my job.

____

____

18. I have the impression that my disease is not being treated properly
by my doctor.

____

____

19. I often cannot ask all my questions when I am with the doctor.
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Appendix F
The Center for Epidemiologic Studies Depression Scale (CESD)
Below is a list of ways you might have felt during the past week. Please indicate how
often you felt or acted the way each statement suggests by using the following scale:
Rarely or none of the time (Less than 1 day)
Some or a little of the time (1-2 days)
Occasionally or a moderate amount of time (3-4 days)
Most all of the time (5-7 days)
Rarely

Some of
the Time

Moderate
Amount
of Time

Most of
the Time

1. I was bothered by things that usually
don’t bother me.

_____

_____

_____

_____

2. I did not feel like eating; my appetite
was poor.

_____

_____

_____

_____

3. I felt that I could not shake off the
blues even with help from my family or
friends.

_____

_____

_____

_____

4. I felt that I was just as good as other
people.

_____

_____

_____

_____

5. I had trouble keeping my mind on
what I was doing.

_____

_____

_____

_____

6. I felt depressed.

_____

_____

_____

_____

7. I felt that everything I did was an
effort.

_____

_____

_____

_____

8. I felt hopeful about the future.

_____

_____

_____

_____

9. I thought my life had been a failure.

_____

_____

_____

_____

10. I felt fearful.

_____

_____

_____

_____

11. My sleep was restless.

_____

_____

_____

_____
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Appendix F, continued
The Center for Epidemiologic Studies Scale (CESD)
Below is a list of ways you might have felt during the past week. Please indicate how
often you felt or acted the way each statement suggests by using the following scale:
Rarely or none of the time (Less than 1 day)
Some or a little of the time (1-2 days)
Occasionally or a moderate amount of time (3-4 days)
Most all of the time (5-7 days)
Rarely

Some of
the Time

Moderate
Amount
of Time

Most of
the Time

12. I was happy.

_____

_____

_____

_____

13. I talked less than usual.

_____

_____

_____

_____

14. I felt lonely.

_____

_____

_____

_____

15. People were unfriendly.

_____

_____

_____

_____

16. I enjoyed life.

_____

_____

_____

_____

17. I had crying spells.

_____

_____

_____

_____

18. I felt sad.

_____

_____

_____

_____

19. I felt that people disliked me.

_____

_____

_____

_____

20. I could not get “going.”

_____

_____

_____

_____
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Appendix G
Intrusiveness of Illness Scale
Using the scale below, check or circle the number that expresses how much you feel
your Parkinson’s disease interferes with the following aspects of your life.
My illness interferes with my…
Very Little

A Great Deal

Body Image

1

2

3

4

5

6

7

Eating Habits

1

2

3

4

5

6

7

Ability to Work

1

2

3

4

5

6

7

Financial Security

1

2

3

4

5

6

7

Preferred Recreation/Leisure

1

2

3

4

5

6

7

Responsibility in the Family

1

2

3

4

5

6

7

Family Relationships

1

2

3

4

5

6

7

Marital Relationships

1

2

3

4

5

6

7

Sexual Relationships

1

2

3

4

5

6

7
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Appendix G, continued
Intrusiveness of Illness Scale
Using the scale below, check or circle the number that expresses how much you feel
your Parkinson’s disease interferes with the following aspects of your life.
My illness interferes with my…
Very Little

A Great
Deal

Personal Relationships with Friends

1

2

3

4

5

6

7

Plans for the Future

1

2

3

4

5

6

7

Freedom to Choose Time Alone

1

2

3

4

5

6

7

Ability to Express My Personality

1

2

3

4

5

6

7

Sense of Independence

1

2

3

4

5

6

7

Self-Esteem

1

2

3

4

5

6

7
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Appendix H
Social Provisions Scale (SPS)
In answering the following questions, think about your current relationships with friends,
family members, co-workers, community members, and so on. Please indicate to what
extent each statement describes your current relationships with other people (check one
answer for each item).
Strongly
Disagree

Disagree

Agree

Strongly
Agree

1. There are people I can depend on to
help me if I really need it.

_____

_____

_____

_____

2. I feel that I do not have close personal
relationships with other people.

_____

_____

_____

_____

3. There is no one I can turn to for
guidance in times of stress.

_____

_____

_____

_____

4. There are people who depend on me
for help.

_____

_____

_____

_____

5. There are people who enjoy the same
social activities I do.

_____

_____

_____

_____

6. Other people do not view me as
competent.

_____

_____

_____

_____

7. I feel personally responsible for the
well-being of another person.

_____

_____

_____

_____

8. I feel part of a group who share my
attitudes and beliefs.

_____

_____

_____

_____

9. I do not thing other people respect my
skills and abilities.

_____

_____

_____

_____

10. If something went wrong, no one
would come to my rescue.

_____

_____

_____

_____

11. I have close relationships that provide
me with a sense of emotional security and
well-being.

_____

_____

_____

_____
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Appendix H, continued
Social Provisions Scale (SPS)
Strongly
Disagree

Disagree

Agree

Strongly
Agree

12. There is someone I could talk to about
important decisions in my life.

_____

_____

_____

_____

13. I have relationships where my
competence and skill are recognized.

_____

_____

_____

_____

14. There is no one who shares my
interests and concerns.

_____

_____

_____

_____

15. There is no one who really relies on
me for their well-being.

_____

_____

_____

_____

16. There is a trustworthy person I could
turn to for advice if I were having
problems.

_____

_____

_____

_____

17. I feel a strong emotional bond with at
least one other person.

_____

_____

_____

_____

18. There is no one I can depend on for
aid if I really need it.

_____

_____

_____

_____

19. There is no one I feel comfortable
talking about problems with.

_____

_____

_____

_____

20. There are people who admire my
talents and abilities.

_____

_____

_____

_____

21. I lack a feeling of intimacy with
another person.

_____

_____

_____

_____

22. There is no one who likes to do the
things I do.

_____

_____

_____

_____

23. There are people I can count on in an
emergency.

_____

_____

_____

_____

24. No one needs me to care for them.

_____

_____

_____

_____
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Appendix I
Life Orientation Test (Optimism)
Indicate the extent to which you agree with each of the items below. Be as accurate and
honest as you can. There are no right or wrong answers (check one for each item).
Strongly
Agree

Agree

Neutral

Disagree

Strongly
Disagree

1. In uncertain times, I usually
expect the best.

_____

_____

______

_____

_____

2. It’s easy for me to relax.

_____

_____

______

_____

_____

3. If something can go wrong
for me, it will.

_____

_____

______

_____

_____

4. I always look on the bright
side of things.

_____

_____

______

_____

_____

5. I’m always optimistic about
my future.

_____

_____

______

_____

_____

6. I enjoy me friends a lot.

_____

_____

______

_____

_____

7. It’s important for me to
keep busy.

_____

_____

______

_____

_____

8. I hardly ever expect things
to go my way.

_____

_____

______

_____

_____

9. Things never work out the
way I want them to.

_____

_____

______

_____

_____

10. I don’t get upset easily.

_____

_____

______

_____

_____

11. I’m a believer in the idea
that “every cloud has a silver
lining.”

_____

_____

______

_____

_____

12. I rarely count on good
things happening to me.

_____

_____

______

_____

_____
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Appendix J
Participant Demographics
INFORMATION ABOUT YOU
1. What is your current living situation? (check one)
_____Living with a partner or family member
_____Living with a friend or roommate
_____Living alone
_____Living in a residential setting
2. What is your current marital status? (check one)
_____Never been married
_____Married or living with partner
_____Separated or divorced
_____Widowed
3. If you are married to your partner, how long have you been married? _____
4. If you are married, is this your: (check one)
_____first marriage
_____second marriage
_____third marriage
5. Do you have paid employment right now? (check one)
_____No
_____Yes, part-time
_____Yes, full-time
6. Do you currently do any volunteer work?
_____Yes
_____No
_____I used to, but no longer do
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Appendix J, continued
Participant Demographics
7. If not currently employed, what is the main reason? (please check one box only)
_____Temporarily laid off
_____Retired by my own choice
_____Forced to retire by my employer
_____Retired on physician’s advice
_____Homemaker
_____Poor health
_____My job was too stressful, or physically demanding
_____Other reason (specify): ________________________________________
8. Do you have any other chronic health problems (e.g., diabetes, heart condition, high
blood pressure)? (check one)
_____Yes If yes, please describe: _________________________________________
_____No

134

Appendix K
Qualitative Interview
1. How do you feel when you reflect back on your experiences in participating in the
fetal tissue surgery trial?

2. Have your feelings regarding your participation in the surgery trial changed over the
last 13-15 years?

3. Would you volunteer to participate in a future study? Why or why not?

4. What was the most positive aspect of participating in the study?

5. What was the most negative aspect of participating in the study?

6. What advice would you give to future participants in terms of coping with
participating in a surgery trial?
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